Diazepam	haloperidol	9	11	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3322	5093	D003975	D006220
Diazepam	haloperidol	9	11	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3322	5093	D003975	D006220
Diazepam	haloperidol	10	11	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3322	5093	D003975	D006220
Diazepam	haloperidol	10	11	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3322	5093	D003975	D006220
Diazepam	haloperidol	10	12	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		3322	5093	D003975	D006220
Diazepam	haloperidol	10	12	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		3322	5093	D003975	D006220
Diazepam	odv	9	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		3322	none	D003975	none
Diazepam	odv	9	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		3322	none	D003975	none
Diazepam	odv	10	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	none	D003975	none
Diazepam	odv	10	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	none	D003975	none
Diazepam	odv	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		3322	none	D003975	none
Diazepam	odv	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		3322	none	D003975	none
Diazepam	cimetidine	9	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		3322	2541	D003975	2541
Diazepam	cimetidine	9	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		3322	2541	D003975	2541
Diazepam	diazepam	54	54	true	negative	CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		D003975	D003975
Diazepam	diazepam	9	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		D003975	D003975
Diazepam	diazepam	9	10	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		D003975	D003975
Diazepam	diazepam	10	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		D003975	D003975
Diazepam	diazepam	10	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		D003975	D003975
Diazepam	diazepam	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		D003975	D003975
Diazepam	Risperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	none	D003975	none
Diazepam	Risperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	none	D003975	none
Diazepam	alprazolam	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	none	D003975	none
Diazepam	alprazolam	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	none	D003975	none
Diazepam	Indinavir	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		3322	none	D003975	none
Diazepam	Indinavir	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		3322	none	D003975	none
Diazepam	Indinavir	46	47	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		3322	none	D003975	none
Diazepam	Indinavir	46	47	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		3322	none	D003975	none
Diazepam	Venlafaxine	54	54	true	negative	CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		3322	39786	D003975	39786
Diazepam	Venlafaxine	54	54	true	negative	CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		3322	39786	D003975	39786
Diazepam	Venlafaxine	54	53	false	none	In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		3322	39786	D003975	39786
Diazepam	Venlafaxine	54	53	false	none	In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		3322	39786	D003975	39786
Diazepam	Venlafaxine	54	52	false	none	CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		3322	39786	D003975	39786
Diazepam	Venlafaxine	54	52	false	none	CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		3322	39786	D003975	39786
Diazepam	Venlafaxine	54	56	false	none	CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  7.9 Monoamine Oxidase Inhibitors    See Contraindications (4) and Warnings and Precautions (5.2).  7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  		3322	39786	D003975	39786
Diazepam	Venlafaxine	54	56	false	none	CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  7.9 Monoamine Oxidase Inhibitors    See Contraindications (4) and Warnings and Precautions (5.2).  7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  		3322	39786	D003975	39786
Diazepam	Venlafaxine	9	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		3322	39786	D003975	39786
Diazepam	Venlafaxine	9	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		3322	39786	D003975	39786
Diazepam	Venlafaxine	9	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		3322	39786	D003975	39786
Diazepam	Venlafaxine	9	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		3322	39786	D003975	39786
Diazepam	Venlafaxine	9	10	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	39786	D003975	39786
Diazepam	Venlafaxine	9	10	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	39786	D003975	39786
Diazepam	Venlafaxine	9	11	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3322	39786	D003975	39786
Diazepam	Venlafaxine	9	11	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3322	39786	D003975	39786
Diazepam	Venlafaxine	10	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	39786	D003975	39786
Diazepam	Venlafaxine	10	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	39786	D003975	39786
Diazepam	Venlafaxine	10	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	39786	D003975	39786
Diazepam	Venlafaxine	10	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	39786	D003975	39786
Diazepam	Venlafaxine	10	11	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3322	39786	D003975	39786
Diazepam	Venlafaxine	10	11	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3322	39786	D003975	39786
Diazepam	Venlafaxine	10	12	true	negative	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		3322	39786	D003975	39786
Diazepam	Venlafaxine	10	12	true	negative	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		3322	39786	D003975	39786
Diazepam	Venlafaxine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	39786	D003975	39786
Diazepam	Venlafaxine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	39786	D003975	39786
Diazepam	Venlafaxine	46	47	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		3322	39786	D003975	39786
Diazepam	Venlafaxine	46	47	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		3322	39786	D003975	39786
Diazepam	Venlafaxine	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	39786	D003975	39786
Diazepam	Venlafaxine	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	39786	D003975	39786
Diazepam	Venlafaxine	46	45	true	negative	CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	39786	D003975	39786
Diazepam	Venlafaxine	46	45	true	negative	CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	39786	D003975	39786
Diazepam	Venlafaxine	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		3322	39786	D003975	39786
Diazepam	Venlafaxine	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		3322	39786	D003975	39786
Diazepam	risperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	none	D003975	none
Diazepam	risperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	none	D003975	none
Diazepam	terfenadine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	none	D003975	none
Diazepam	terfenadine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	none	D003975	none
Diazepam	tolbutamide	54	53	false	none	In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		3322	none	D003975	none
Diazepam	tolbutamide	54	53	false	none	In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		3322	none	D003975	none
Diazepam	desmethyldiazepam	9	10	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	3155	D003975	D003708
Diazepam	desmethyldiazepam	9	10	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	3155	D003975	D003708
Diazepam	desmethyldiazepam	10	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	3155	D003975	D003708
Diazepam	desmethyldiazepam	10	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	3155	D003975	D003708
Diazepam	indinavir	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		3322	none	D003975	none
Diazepam	indinavir	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		3322	none	D003975	none
Diazepam	indinavir	46	47	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		3322	none	D003975	none
Diazepam	indinavir	46	47	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		3322	none	D003975	none
Diazepam	venlafaxine	54	54	true	negative	CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		3322	39786	D003975	39786
Diazepam	venlafaxine	54	54	true	negative	CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		3322	39786	D003975	39786
Diazepam	venlafaxine	54	53	false	none	In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		3322	39786	D003975	39786
Diazepam	venlafaxine	54	53	false	none	In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		3322	39786	D003975	39786
Diazepam	venlafaxine	54	52	false	none	CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		3322	39786	D003975	39786
Diazepam	venlafaxine	54	52	false	none	CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		3322	39786	D003975	39786
Diazepam	venlafaxine	54	56	false	none	CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  7.9 Monoamine Oxidase Inhibitors    See Contraindications (4) and Warnings and Precautions (5.2).  7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  		3322	39786	D003975	39786
Diazepam	venlafaxine	54	56	false	none	CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  7.9 Monoamine Oxidase Inhibitors    See Contraindications (4) and Warnings and Precautions (5.2).  7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  		3322	39786	D003975	39786
Diazepam	venlafaxine	9	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		3322	39786	D003975	39786
Diazepam	venlafaxine	9	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		3322	39786	D003975	39786
Diazepam	venlafaxine	9	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		3322	39786	D003975	39786
Diazepam	venlafaxine	9	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		3322	39786	D003975	39786
Diazepam	venlafaxine	9	10	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	39786	D003975	39786
Diazepam	venlafaxine	9	10	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	39786	D003975	39786
Diazepam	venlafaxine	9	11	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3322	39786	D003975	39786
Diazepam	venlafaxine	9	11	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3322	39786	D003975	39786
Diazepam	venlafaxine	10	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	39786	D003975	39786
Diazepam	venlafaxine	10	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	39786	D003975	39786
Diazepam	venlafaxine	10	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	39786	D003975	39786
Diazepam	venlafaxine	10	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	39786	D003975	39786
Diazepam	venlafaxine	10	11	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3322	39786	D003975	39786
Diazepam	venlafaxine	10	11	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3322	39786	D003975	39786
Diazepam	venlafaxine	10	12	true	negative	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		3322	39786	D003975	39786
Diazepam	venlafaxine	10	12	true	negative	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		3322	39786	D003975	39786
Diazepam	venlafaxine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	39786	D003975	39786
Diazepam	venlafaxine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	39786	D003975	39786
Diazepam	venlafaxine	46	47	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		3322	39786	D003975	39786
Diazepam	venlafaxine	46	47	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		3322	39786	D003975	39786
Diazepam	venlafaxine	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	39786	D003975	39786
Diazepam	venlafaxine	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	39786	D003975	39786
Diazepam	venlafaxine	46	45	true	negative	CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	39786	D003975	39786
Diazepam	venlafaxine	46	45	true	negative	CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	39786	D003975	39786
Diazepam	venlafaxine	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		3322	39786	D003975	39786
Diazepam	venlafaxine	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		3322	39786	D003975	39786
Diazepam	Haloperidol	9	11	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3322	5093	D003975	D006220
Diazepam	Haloperidol	9	11	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3322	5093	D003975	D006220
Diazepam	Haloperidol	10	11	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3322	5093	D003975	D006220
Diazepam	Haloperidol	10	11	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3322	5093	D003975	D006220
Diazepam	Haloperidol	10	12	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		3322	5093	D003975	D006220
Diazepam	Haloperidol	10	12	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		3322	5093	D003975	D006220
Diazepam	9-hydroxyrisperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	none	D003975	none
Diazepam	9-hydroxyrisperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	none	D003975	none
Diazepam	Cimetidine	9	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		3322	2541	D003975	2541
Diazepam	Cimetidine	9	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		3322	2541	D003975	2541
haloperidol	odv	11	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		5093	none	D006220	none
haloperidol	odv	11	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		5093	none	D006220	none
haloperidol	diazepam	11	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		5093	3322	D006220	D003975
haloperidol	diazepam	11	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		5093	3322	D006220	D003975
haloperidol	diazepam	11	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		5093	3322	D006220	D003975
haloperidol	diazepam	11	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		5093	3322	D006220	D003975
haloperidol	diazepam	12	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		5093	3322	D006220	D003975
haloperidol	diazepam	12	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		5093	3322	D006220	D003975
haloperidol	Venlafaxine	11	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		5093	39786	D006220	39786
haloperidol	Venlafaxine	11	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		5093	39786	D006220	39786
haloperidol	Venlafaxine	11	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		5093	39786	D006220	39786
haloperidol	Venlafaxine	11	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		5093	39786	D006220	39786
haloperidol	Venlafaxine	11	11	true	positive	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		5093	39786	D006220	39786
haloperidol	Venlafaxine	11	11	true	positive	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		5093	39786	D006220	39786
haloperidol	Venlafaxine	11	12	false	none	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		5093	39786	D006220	39786
haloperidol	Venlafaxine	11	12	false	none	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		5093	39786	D006220	39786
haloperidol	Venlafaxine	12	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		5093	39786	D006220	39786
haloperidol	Venlafaxine	12	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		5093	39786	D006220	39786
haloperidol	Venlafaxine	12	11	false	none	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		5093	39786	D006220	39786
haloperidol	Venlafaxine	12	11	false	none	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		5093	39786	D006220	39786
haloperidol	Venlafaxine	12	12	false	none	In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		5093	39786	D006220	39786
haloperidol	Venlafaxine	12	12	false	none	In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		5093	39786	D006220	39786
haloperidol	Venlafaxine	12	14	true	negative	In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  The mechanism explaining this finding is unknown.  7.5 Lithium    The steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects.  		5093	39786	D006220	39786
haloperidol	Venlafaxine	12	14	true	negative	In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  The mechanism explaining this finding is unknown.  7.5 Lithium    The steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects.  		5093	39786	D006220	39786
haloperidol	desmethyldiazepam	11	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		5093	3155	D006220	D003708
haloperidol	desmethyldiazepam	11	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		5093	3155	D006220	D003708
haloperidol	desmethyldiazepam	12	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		5093	3155	D006220	D003708
haloperidol	desmethyldiazepam	12	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		5093	3155	D006220	D003708
haloperidol	venlafaxine	11	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		5093	39786	D006220	39786
haloperidol	venlafaxine	11	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		5093	39786	D006220	39786
haloperidol	venlafaxine	11	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		5093	39786	D006220	39786
haloperidol	venlafaxine	11	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		5093	39786	D006220	39786
haloperidol	venlafaxine	11	11	true	positive	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		5093	39786	D006220	39786
haloperidol	venlafaxine	11	11	true	positive	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		5093	39786	D006220	39786
haloperidol	venlafaxine	11	12	false	none	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		5093	39786	D006220	39786
haloperidol	venlafaxine	11	12	false	none	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		5093	39786	D006220	39786
haloperidol	venlafaxine	12	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		5093	39786	D006220	39786
haloperidol	venlafaxine	12	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		5093	39786	D006220	39786
haloperidol	venlafaxine	12	11	false	none	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		5093	39786	D006220	39786
haloperidol	venlafaxine	12	11	false	none	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		5093	39786	D006220	39786
haloperidol	venlafaxine	12	12	false	none	In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		5093	39786	D006220	39786
haloperidol	venlafaxine	12	12	false	none	In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		5093	39786	D006220	39786
haloperidol	venlafaxine	12	14	true	negative	In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  The mechanism explaining this finding is unknown.  7.5 Lithium    The steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects.  		5093	39786	D006220	39786
haloperidol	venlafaxine	12	14	true	negative	In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  The mechanism explaining this finding is unknown.  7.5 Lithium    The steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects.  		5093	39786	D006220	39786
haloperidol	Haloperidol	11	11	true	positive	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		D006220	D006220
haloperidol	Haloperidol	11	12	false	none	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		D006220	D006220
haloperidol	Haloperidol	12	11	false	none	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		D006220	D006220
haloperidol	Haloperidol	12	12	false	none	In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		D006220	D006220
quinidine	odv	20	19	false	none	Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  		9068	none	9068	none
quinidine	odv	20	19	false	none	Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  		9068	none	9068	none
quinidine	odv	20	18	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  		9068	none	9068	none
quinidine	odv	20	18	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  		9068	none	9068	none
quinidine	odv	20	22	false	none	CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		9068	none	9068	none
quinidine	odv	20	22	false	none	CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		9068	none	9068	none
quinidine	Ketoconazole	20	22	false	none	CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		9068	6135	9068	D007654
quinidine	Ketoconazole	20	22	false	none	CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		9068	6135	9068	D007654
quinidine	ketoconazole	20	22	false	none	CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		9068	6135	9068	D007654
quinidine	ketoconazole	20	22	false	none	CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		9068	6135	9068	D007654
quinidine	Venlafaxine	20	19	false	none	Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  		9068	39786	9068	39786
quinidine	Venlafaxine	20	19	false	none	Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  		9068	39786	9068	39786
quinidine	Venlafaxine	20	18	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  		9068	39786	9068	39786
quinidine	Venlafaxine	20	18	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  		9068	39786	9068	39786
quinidine	Venlafaxine	20	21	false	none	CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  		9068	39786	9068	39786
quinidine	Venlafaxine	20	21	false	none	CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  		9068	39786	9068	39786
quinidine	Venlafaxine	20	22	false	none	CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		9068	39786	9068	39786
quinidine	Venlafaxine	20	22	false	none	CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		9068	39786	9068	39786
quinidine	venlafaxine	20	19	false	none	Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  		9068	39786	9068	39786
quinidine	venlafaxine	20	19	false	none	Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  		9068	39786	9068	39786
quinidine	venlafaxine	20	18	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  		9068	39786	9068	39786
quinidine	venlafaxine	20	18	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  		9068	39786	9068	39786
quinidine	venlafaxine	20	21	false	none	CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  		9068	39786	9068	39786
quinidine	venlafaxine	20	21	false	none	CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  		9068	39786	9068	39786
quinidine	venlafaxine	20	22	false	none	CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		9068	39786	9068	39786
quinidine	venlafaxine	20	22	false	none	CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		9068	39786	9068	39786
quinidine	p450	20	18	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  		9068	none	9068	none
quinidine	p450	20	18	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  		9068	none	9068	none
Warfarin	Venlafaxine hydrochloride	70	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	none	none	none
Warfarin	Venlafaxine hydrochloride	66	68	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	none	none	none
Warfarin	Venlafaxine hydrochloride	66	67	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	none	none	none
Warfarin	Venlafaxine hydrochloride	67	68	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	none	none	none
Warfarin	Venlafaxine hydrochloride	67	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	none	none	none
Warfarin	Venlafaxine hydrochloride	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
Warfarin	Aspirin	66	65	false	none	These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  		none	none	none	none
Warfarin	Aspirin	67	65	false	none	These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	none	none	none
Warfarin	Aspirin	63	65	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  		none	none	none	none
Warfarin	Aspirin	63	63	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
Warfarin	thromboplastin	70	70	false	none	There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	none	none	none
Warfarin	warfarin	70	70	false	none	There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	none	none	none
Warfarin	warfarin	66	66	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  		none	none	none	none
Warfarin	warfarin	66	67	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	none	none	none
Warfarin	warfarin	67	66	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	none	none	none
Warfarin	warfarin	67	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	none	none	none
Warfarin	warfarin	63	63	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
Warfarin	prothrombin	70	70	false	none	There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	none	none	none
Warfarin	Serotonin	66	64	false	none	Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  		none	none	none	none
Warfarin	Serotonin	63	64	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  		none	none	none	none
Warfarin	Serotonin	63	63	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
Warfarin	Serotonin	63	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
Warfarin	Venlafaxine	70	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
Warfarin	Venlafaxine	70	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
Warfarin	Venlafaxine	70	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
Warfarin	Venlafaxine	70	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
Warfarin	Venlafaxine	70	70	false	none	There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
Warfarin	Venlafaxine	70	70	false	none	There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
Warfarin	Venlafaxine	66	68	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	39786
Warfarin	Venlafaxine	66	68	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	39786
Warfarin	Venlafaxine	66	67	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	39786
Warfarin	Venlafaxine	66	67	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	39786
Warfarin	Venlafaxine	67	68	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	39786
Warfarin	Venlafaxine	67	68	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	39786
Warfarin	Venlafaxine	67	69	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		none	39786	none	39786
Warfarin	Venlafaxine	67	69	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		none	39786	none	39786
Warfarin	Venlafaxine	67	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	39786
Warfarin	Venlafaxine	67	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	39786
Warfarin	Venlafaxine	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	39786	none	39786
Warfarin	Venlafaxine	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	39786	none	39786
Warfarin	venlafaxine hydrochloride	70	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	C047426
Warfarin	venlafaxine hydrochloride	70	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	C047426
Warfarin	venlafaxine hydrochloride	66	68	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	C047426
Warfarin	venlafaxine hydrochloride	66	68	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	C047426
Warfarin	venlafaxine hydrochloride	66	67	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	C047426
Warfarin	venlafaxine hydrochloride	66	67	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	C047426
Warfarin	venlafaxine hydrochloride	67	68	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	C047426
Warfarin	venlafaxine hydrochloride	67	68	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	C047426
Warfarin	venlafaxine hydrochloride	67	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	C047426
Warfarin	venlafaxine hydrochloride	67	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	C047426
Warfarin	venlafaxine hydrochloride	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	39786	none	C047426
Warfarin	venlafaxine hydrochloride	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	39786	none	C047426
Warfarin	aspirin	66	65	false	none	These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  		none	none	none	none
Warfarin	aspirin	67	65	false	none	These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	none	none	none
Warfarin	aspirin	63	65	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  		none	none	none	none
Warfarin	aspirin	63	63	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
Warfarin	serotonin	66	64	false	none	Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  		none	none	none	none
Warfarin	serotonin	63	64	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  		none	none	none	none
Warfarin	serotonin	63	63	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
Warfarin	serotonin	63	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
Warfarin	venlafaxine	70	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
Warfarin	venlafaxine	70	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
Warfarin	venlafaxine	70	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
Warfarin	venlafaxine	70	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
Warfarin	venlafaxine	70	70	false	none	There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
Warfarin	venlafaxine	70	70	false	none	There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
Warfarin	venlafaxine	66	68	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	39786
Warfarin	venlafaxine	66	68	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	39786
Warfarin	venlafaxine	66	67	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	39786
Warfarin	venlafaxine	66	67	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	39786
Warfarin	venlafaxine	67	68	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	39786
Warfarin	venlafaxine	67	68	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	39786
Warfarin	venlafaxine	67	69	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		none	39786	none	39786
Warfarin	venlafaxine	67	69	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		none	39786	none	39786
Warfarin	venlafaxine	67	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	39786
Warfarin	venlafaxine	67	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	39786
Warfarin	venlafaxine	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	39786	none	39786
Warfarin	venlafaxine	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	39786	none	39786
Warfarin	clozapine	70	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	none	none	none
Warfarin	clozapine	67	69	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		none	none	none	none
Warfarin	triptan	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
Warfarin	triptan	63	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
Imipramine	odv	34	34	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	none	5691	none
Imipramine	odv	34	34	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	none	5691	none
Imipramine	dextrorphan	31	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	none	5691	D003917
Imipramine	dextrorphan	31	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	none	5691	D003917
Imipramine	imipramine	34	34	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	5691
Imipramine	imipramine	31	31	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	5691
Imipramine	Venlafaxine	34	34	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	39786	5691	39786
Imipramine	Venlafaxine	34	34	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	39786	5691	39786
Imipramine	Venlafaxine	34	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	39786	5691	39786
Imipramine	Venlafaxine	34	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	39786	5691	39786
Imipramine	Venlafaxine	34	33	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	39786	5691	39786
Imipramine	Venlafaxine	34	33	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	39786	5691	39786
Imipramine	Venlafaxine	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		5691	39786	5691	39786
Imipramine	Venlafaxine	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		5691	39786	5691	39786
Imipramine	Venlafaxine	31	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	39786	5691	39786
Imipramine	Venlafaxine	31	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	39786	5691	39786
Imipramine	Venlafaxine	31	31	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	39786	5691	39786
Imipramine	Venlafaxine	31	31	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	39786	5691	39786
Imipramine	Venlafaxine	31	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	39786	5691	39786
Imipramine	Venlafaxine	31	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	39786	5691	39786
Imipramine	Venlafaxine	31	32	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		5691	39786	5691	39786
Imipramine	Venlafaxine	31	32	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		5691	39786	5691	39786
Imipramine	Venlafaxine	31	33	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		5691	39786	5691	39786
Imipramine	Venlafaxine	31	33	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		5691	39786	5691	39786
Imipramine	fluoxetine	31	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	4493	5691	D005473
Imipramine	fluoxetine	31	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	4493	5691	D005473
Imipramine	desipramine	34	35	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  		5691	3247	5691	3247
Imipramine	desipramine	34	35	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  		5691	3247	5691	3247
Imipramine	desipramine	34	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	3247	5691	3247
Imipramine	desipramine	34	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	3247	5691	3247
Imipramine	desipramine	34	33	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	3247	5691	3247
Imipramine	desipramine	34	33	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	3247	5691	3247
Imipramine	desipramine	31	32	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		5691	3247	5691	3247
Imipramine	desipramine	31	32	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		5691	3247	5691	3247
Imipramine	desipramine	31	33	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		5691	3247	5691	3247
Imipramine	desipramine	31	33	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		5691	3247	5691	3247
Imipramine	venlafaxine	34	34	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	39786	5691	39786
Imipramine	venlafaxine	34	34	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	39786	5691	39786
Imipramine	venlafaxine	34	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	39786	5691	39786
Imipramine	venlafaxine	34	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	39786	5691	39786
Imipramine	venlafaxine	34	33	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	39786	5691	39786
Imipramine	venlafaxine	34	33	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	39786	5691	39786
Imipramine	venlafaxine	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		5691	39786	5691	39786
Imipramine	venlafaxine	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		5691	39786	5691	39786
Imipramine	venlafaxine	31	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	39786	5691	39786
Imipramine	venlafaxine	31	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	39786	5691	39786
Imipramine	venlafaxine	31	31	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	39786	5691	39786
Imipramine	venlafaxine	31	31	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	39786	5691	39786
Imipramine	venlafaxine	31	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	39786	5691	39786
Imipramine	venlafaxine	31	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	39786	5691	39786
Imipramine	venlafaxine	31	32	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		5691	39786	5691	39786
Imipramine	venlafaxine	31	32	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		5691	39786	5691	39786
Imipramine	venlafaxine	31	33	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		5691	39786	5691	39786
Imipramine	venlafaxine	31	33	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		5691	39786	5691	39786
Imipramine	Metoprolol	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		5691	6918	5691	D008790
Imipramine	Metoprolol	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		5691	6918	5691	D008790
Imipramine	dextromethorphan	31	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	0	5691	D003915
Imipramine	dextromethorphan	31	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	0	5691	D003915
Imipramine	metoprolol	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		5691	6918	5691	D008790
Imipramine	metoprolol	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		5691	6918	5691	D008790
Imipramine	p450	31	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	none	5691	none
Imipramine	p450	31	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	none	5691	none
odv	Ketoconazole	22	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		none	6135	none	D007654
odv	Ketoconazole	22	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		none	6135	none	D007654
odv	Ketoconazole	24	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.  		none	6135	none	D007654
odv	Ketoconazole	24	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.  		none	6135	none	D007654
odv	cimetidine	1	3	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		none	2541	none	2541
odv	cimetidine	1	3	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		none	2541	none	2541
odv	cimetidine	5	3	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		none	2541	none	2541
odv	cimetidine	5	3	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		none	2541	none	2541
odv	cimetidine	5	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		none	2541	none	2541
odv	cimetidine	5	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		none	2541	none	2541
odv	cimetidine	5	7	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		none	2541	none	2541
odv	cimetidine	5	7	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		none	2541	none	2541
odv	cimetidine	6	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		none	2541	none	2541
odv	cimetidine	6	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		none	2541	none	2541
odv	cimetidine	6	7	false	none	The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		none	2541	none	2541
odv	cimetidine	6	7	false	none	The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		none	2541	none	2541
odv	cimetidine	9	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		none	2541	none	2541
odv	cimetidine	9	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		none	2541	none	2541
odv	Venlafaxine hydrochloride	15	17	false	none	ODV also was unaffected.  Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  		none	none	none	none
odv	Venlafaxine hydrochloride	19	17	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		none	none	none	none
odv	Venlafaxine hydrochloride	18	17	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		none	none	none	none
odv	diazepam	9	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		none	3322	none	D003975
odv	diazepam	9	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		none	3322	none	D003975
odv	diazepam	9	10	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		none	3322	none	D003975
odv	diazepam	9	10	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		none	3322	none	D003975
odv	diazepam	48	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	3322	none	D003975
odv	diazepam	48	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	3322	none	D003975
odv	alcohol	1	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  		none	none	none	none
odv	imipramine	34	34	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		none	5691	none	5691
odv	imipramine	34	34	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		none	5691	none	5691
odv	alprazolam	48	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	none	none	none
odv	ketoconazole	22	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		none	6135	none	D007654
odv	ketoconazole	22	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		none	6135	none	D007654
odv	ketoconazole	24	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.  		none	6135	none	D007654
odv	ketoconazole	24	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.  		none	6135	none	D007654
odv	Indinavir	48	48	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	none	none	none
odv	Indinavir	48	47	true	negative	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	none	none	none
odv	Venlafaxine	34	34	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
odv	Venlafaxine	34	34	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
odv	Venlafaxine	34	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
odv	Venlafaxine	34	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
odv	Venlafaxine	34	33	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
odv	Venlafaxine	34	33	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
odv	Venlafaxine	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		none	39786	none	39786
odv	Venlafaxine	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		none	39786	none	39786
odv	Venlafaxine	1	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  		none	39786	none	39786
odv	Venlafaxine	1	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  		none	39786	none	39786
odv	Venlafaxine	1	2	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  		none	39786	none	39786
odv	Venlafaxine	1	2	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  		none	39786	none	39786
odv	Venlafaxine	1	3	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		none	39786	none	39786
odv	Venlafaxine	1	3	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		none	39786	none	39786
odv	Venlafaxine	5	3	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		none	39786	none	39786
odv	Venlafaxine	5	3	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		none	39786	none	39786
odv	Venlafaxine	5	4	false	none	The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		none	39786	none	39786
odv	Venlafaxine	5	4	false	none	The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		none	39786	none	39786
odv	Venlafaxine	5	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		none	39786	none	39786
odv	Venlafaxine	5	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		none	39786	none	39786
odv	Venlafaxine	5	6	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		none	39786	none	39786
odv	Venlafaxine	5	6	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		none	39786	none	39786
odv	Venlafaxine	5	7	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		none	39786	none	39786
odv	Venlafaxine	5	7	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		none	39786	none	39786
odv	Venlafaxine	6	4	false	none	The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		none	39786	none	39786
odv	Venlafaxine	6	4	false	none	The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		none	39786	none	39786
odv	Venlafaxine	6	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		none	39786	none	39786
odv	Venlafaxine	6	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		none	39786	none	39786
odv	Venlafaxine	6	6	false	none	The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		none	39786	none	39786
odv	Venlafaxine	6	6	false	none	The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		none	39786	none	39786
odv	Venlafaxine	6	7	false	none	The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		none	39786	none	39786
odv	Venlafaxine	6	7	false	none	The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		none	39786	none	39786
odv	Venlafaxine	9	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		none	39786	none	39786
odv	Venlafaxine	9	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		none	39786	none	39786
odv	Venlafaxine	9	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		none	39786	none	39786
odv	Venlafaxine	9	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		none	39786	none	39786
odv	Venlafaxine	9	10	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		none	39786	none	39786
odv	Venlafaxine	9	10	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		none	39786	none	39786
odv	Venlafaxine	9	11	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		none	39786	none	39786
odv	Venlafaxine	9	11	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		none	39786	none	39786
odv	Venlafaxine	15	14	true	negative	7.5 Lithium    The steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects.  ODV also was unaffected.  		none	39786	none	39786
odv	Venlafaxine	15	14	true	negative	7.5 Lithium    The steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects.  ODV also was unaffected.  		none	39786	none	39786
odv	Venlafaxine	15	17	false	none	ODV also was unaffected.  Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  		none	39786	none	39786
odv	Venlafaxine	15	17	false	none	ODV also was unaffected.  Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  		none	39786	none	39786
odv	Venlafaxine	15	16	true	negative	ODV also was unaffected.  Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  		none	39786	none	39786
odv	Venlafaxine	15	16	true	negative	ODV also was unaffected.  Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  		none	39786	none	39786
odv	Venlafaxine	19	17	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		none	39786	none	39786
odv	Venlafaxine	19	17	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		none	39786	none	39786
odv	Venlafaxine	19	19	false	none	Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		none	39786	none	39786
odv	Venlafaxine	19	19	false	none	Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		none	39786	none	39786
odv	Venlafaxine	19	18	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		none	39786	none	39786
odv	Venlafaxine	19	18	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		none	39786	none	39786
odv	Venlafaxine	19	21	false	none	Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  		none	39786	none	39786
odv	Venlafaxine	19	21	false	none	Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  		none	39786	none	39786
odv	Venlafaxine	48	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
odv	Venlafaxine	48	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
odv	Venlafaxine	48	47	true	negative	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
odv	Venlafaxine	48	47	true	negative	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
odv	Venlafaxine	48	50	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of this finding is unknown.  CYP1A2    Venlafaxine did not inhibit CYP1A2 in vitro.  		none	39786	none	39786
odv	Venlafaxine	48	50	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of this finding is unknown.  CYP1A2    Venlafaxine did not inhibit CYP1A2 in vitro.  		none	39786	none	39786
odv	Venlafaxine	48	48	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
odv	Venlafaxine	48	48	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
odv	Venlafaxine	18	17	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		none	39786	none	39786
odv	Venlafaxine	18	17	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		none	39786	none	39786
odv	Venlafaxine	18	16	false	none	Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		none	39786	none	39786
odv	Venlafaxine	18	16	false	none	Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		none	39786	none	39786
odv	Venlafaxine	18	19	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		none	39786	none	39786
odv	Venlafaxine	18	19	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		none	39786	none	39786
odv	Venlafaxine	18	18	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		none	39786	none	39786
odv	Venlafaxine	18	18	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		none	39786	none	39786
odv	Venlafaxine	22	21	false	none	Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		none	39786	none	39786
odv	Venlafaxine	22	21	false	none	Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		none	39786	none	39786
odv	Venlafaxine	22	23	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  		none	39786	none	39786
odv	Venlafaxine	22	23	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  		none	39786	none	39786
odv	Venlafaxine	22	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		none	39786	none	39786
odv	Venlafaxine	22	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		none	39786	none	39786
odv	Venlafaxine	25	23	true	positive	Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.  Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  		none	39786	none	39786
odv	Venlafaxine	25	23	true	positive	Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.  Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  		none	39786	none	39786
odv	Venlafaxine	25	25	true	positive	Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  		none	39786	none	39786
odv	Venlafaxine	25	25	true	positive	Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  		none	39786	none	39786
odv	Venlafaxine	25	27	true	positive	Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  		none	39786	none	39786
odv	Venlafaxine	25	27	true	positive	Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  		none	39786	none	39786
odv	Venlafaxine	25	26	true	positive	Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  		none	39786	none	39786
odv	Venlafaxine	25	26	true	positive	Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  		none	39786	none	39786
odv	Venlafaxine	24	23	true	positive	Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.  		none	39786	none	39786
odv	Venlafaxine	24	23	true	positive	Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.  		none	39786	none	39786
odv	Venlafaxine	24	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.  		none	39786	none	39786
odv	Venlafaxine	24	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.  		none	39786	none	39786
odv	Venlafaxine	24	25	true	positive	Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.  Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  		none	39786	none	39786
odv	Venlafaxine	24	25	true	positive	Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.  Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  		none	39786	none	39786
odv	Venlafaxine	24	26	true	positive	Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.  Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  		none	39786	none	39786
odv	Venlafaxine	24	26	true	positive	Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.  Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  		none	39786	none	39786
odv	Venlafaxine	27	25	true	positive	Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  		none	39786	none	39786
odv	Venlafaxine	27	25	true	positive	Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  		none	39786	none	39786
odv	Venlafaxine	27	27	false	none	Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  		none	39786	none	39786
odv	Venlafaxine	27	27	false	none	Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  		none	39786	none	39786
odv	Venlafaxine	27	26	true	positive	Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  		none	39786	none	39786
odv	Venlafaxine	27	26	true	positive	Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  		none	39786	none	39786
odv	Venlafaxine	27	29	false	none	Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  		none	39786	none	39786
odv	Venlafaxine	27	29	false	none	Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  		none	39786	none	39786
odv	Venlafaxine	27	28	false	none	Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  		none	39786	none	39786
odv	Venlafaxine	27	28	false	none	Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  		none	39786	none	39786
odv	Venlafaxine	26	25	true	positive	Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  		none	39786	none	39786
odv	Venlafaxine	26	25	true	positive	Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  		none	39786	none	39786
odv	Venlafaxine	26	27	true	positive	Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  		none	39786	none	39786
odv	Venlafaxine	26	27	true	positive	Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  		none	39786	none	39786
odv	Venlafaxine	26	26	true	positive	Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  		none	39786	none	39786
odv	Venlafaxine	26	26	true	positive	Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  		none	39786	none	39786
odv	Venlafaxine	26	28	true	positive	Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  		none	39786	none	39786
odv	Venlafaxine	26	28	true	positive	Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  		none	39786	none	39786
odv	venlafaxine hydrochloride	15	17	false	none	ODV also was unaffected.  Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  		none	39786	none	C047426
odv	venlafaxine hydrochloride	15	17	false	none	ODV also was unaffected.  Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  		none	39786	none	C047426
odv	venlafaxine hydrochloride	19	17	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		none	39786	none	C047426
odv	venlafaxine hydrochloride	19	17	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		none	39786	none	C047426
odv	venlafaxine hydrochloride	18	17	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		none	39786	none	C047426
odv	venlafaxine hydrochloride	18	17	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		none	39786	none	C047426
odv	terfenadine	48	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	none	none	none
odv	desmethyldiazepam	9	10	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		none	3155	none	D003708
odv	desmethyldiazepam	9	10	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		none	3155	none	D003708
odv	desipramine	34	35	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  		none	3247	none	3247
odv	desipramine	34	35	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  		none	3247	none	3247
odv	desipramine	34	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		none	3247	none	3247
odv	desipramine	34	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		none	3247	none	3247
odv	desipramine	34	33	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		none	3247	none	3247
odv	desipramine	34	33	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		none	3247	none	3247
odv	ethanol	1	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  		none	448	none	D000431
odv	ethanol	1	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  		none	448	none	D000431
odv	ethanol	1	2	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  		none	448	none	D000431
odv	ethanol	1	2	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  		none	448	none	D000431
odv	indinavir	48	48	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	none	none	none
odv	indinavir	48	47	true	negative	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	none	none	none
odv	venlafaxine	34	34	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
odv	venlafaxine	34	34	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
odv	venlafaxine	34	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
odv	venlafaxine	34	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
odv	venlafaxine	34	33	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
odv	venlafaxine	34	33	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
odv	venlafaxine	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		none	39786	none	39786
odv	venlafaxine	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		none	39786	none	39786
odv	venlafaxine	1	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  		none	39786	none	39786
odv	venlafaxine	1	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  		none	39786	none	39786
odv	venlafaxine	1	2	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  		none	39786	none	39786
odv	venlafaxine	1	2	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  		none	39786	none	39786
odv	venlafaxine	1	3	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		none	39786	none	39786
odv	venlafaxine	1	3	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		none	39786	none	39786
odv	venlafaxine	5	3	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		none	39786	none	39786
odv	venlafaxine	5	3	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		none	39786	none	39786
odv	venlafaxine	5	4	false	none	The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		none	39786	none	39786
odv	venlafaxine	5	4	false	none	The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		none	39786	none	39786
odv	venlafaxine	5	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		none	39786	none	39786
odv	venlafaxine	5	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		none	39786	none	39786
odv	venlafaxine	5	6	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		none	39786	none	39786
odv	venlafaxine	5	6	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		none	39786	none	39786
odv	venlafaxine	5	7	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		none	39786	none	39786
odv	venlafaxine	5	7	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		none	39786	none	39786
odv	venlafaxine	6	4	false	none	The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		none	39786	none	39786
odv	venlafaxine	6	4	false	none	The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		none	39786	none	39786
odv	venlafaxine	6	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		none	39786	none	39786
odv	venlafaxine	6	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		none	39786	none	39786
odv	venlafaxine	6	6	false	none	The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		none	39786	none	39786
odv	venlafaxine	6	6	false	none	The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		none	39786	none	39786
odv	venlafaxine	6	7	false	none	The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		none	39786	none	39786
odv	venlafaxine	6	7	false	none	The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		none	39786	none	39786
odv	venlafaxine	9	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		none	39786	none	39786
odv	venlafaxine	9	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		none	39786	none	39786
odv	venlafaxine	9	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		none	39786	none	39786
odv	venlafaxine	9	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		none	39786	none	39786
odv	venlafaxine	9	10	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		none	39786	none	39786
odv	venlafaxine	9	10	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		none	39786	none	39786
odv	venlafaxine	9	11	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		none	39786	none	39786
odv	venlafaxine	9	11	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		none	39786	none	39786
odv	venlafaxine	15	14	true	negative	7.5 Lithium    The steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects.  ODV also was unaffected.  		none	39786	none	39786
odv	venlafaxine	15	14	true	negative	7.5 Lithium    The steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects.  ODV also was unaffected.  		none	39786	none	39786
odv	venlafaxine	15	17	false	none	ODV also was unaffected.  Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  		none	39786	none	39786
odv	venlafaxine	15	17	false	none	ODV also was unaffected.  Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  		none	39786	none	39786
odv	venlafaxine	15	16	true	negative	ODV also was unaffected.  Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  		none	39786	none	39786
odv	venlafaxine	15	16	true	negative	ODV also was unaffected.  Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  		none	39786	none	39786
odv	venlafaxine	19	17	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		none	39786	none	39786
odv	venlafaxine	19	17	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		none	39786	none	39786
odv	venlafaxine	19	19	false	none	Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		none	39786	none	39786
odv	venlafaxine	19	19	false	none	Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		none	39786	none	39786
odv	venlafaxine	19	18	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		none	39786	none	39786
odv	venlafaxine	19	18	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		none	39786	none	39786
odv	venlafaxine	19	21	false	none	Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  		none	39786	none	39786
odv	venlafaxine	19	21	false	none	Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  		none	39786	none	39786
odv	venlafaxine	48	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
odv	venlafaxine	48	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
odv	venlafaxine	48	47	true	negative	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
odv	venlafaxine	48	47	true	negative	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
odv	venlafaxine	48	50	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of this finding is unknown.  CYP1A2    Venlafaxine did not inhibit CYP1A2 in vitro.  		none	39786	none	39786
odv	venlafaxine	48	50	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of this finding is unknown.  CYP1A2    Venlafaxine did not inhibit CYP1A2 in vitro.  		none	39786	none	39786
odv	venlafaxine	48	48	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
odv	venlafaxine	48	48	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
odv	venlafaxine	18	17	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		none	39786	none	39786
odv	venlafaxine	18	17	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		none	39786	none	39786
odv	venlafaxine	18	16	false	none	Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		none	39786	none	39786
odv	venlafaxine	18	16	false	none	Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		none	39786	none	39786
odv	venlafaxine	18	19	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		none	39786	none	39786
odv	venlafaxine	18	19	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		none	39786	none	39786
odv	venlafaxine	18	18	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		none	39786	none	39786
odv	venlafaxine	18	18	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		none	39786	none	39786
odv	venlafaxine	22	21	false	none	Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		none	39786	none	39786
odv	venlafaxine	22	21	false	none	Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		none	39786	none	39786
odv	venlafaxine	22	23	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  		none	39786	none	39786
odv	venlafaxine	22	23	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  		none	39786	none	39786
odv	venlafaxine	22	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		none	39786	none	39786
odv	venlafaxine	22	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		none	39786	none	39786
odv	venlafaxine	25	23	true	positive	Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.  Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  		none	39786	none	39786
odv	venlafaxine	25	23	true	positive	Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.  Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  		none	39786	none	39786
odv	venlafaxine	25	25	true	positive	Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  		none	39786	none	39786
odv	venlafaxine	25	25	true	positive	Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  		none	39786	none	39786
odv	venlafaxine	25	27	true	positive	Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  		none	39786	none	39786
odv	venlafaxine	25	27	true	positive	Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  		none	39786	none	39786
odv	venlafaxine	25	26	true	positive	Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  		none	39786	none	39786
odv	venlafaxine	25	26	true	positive	Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  		none	39786	none	39786
odv	venlafaxine	24	23	true	positive	Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.  		none	39786	none	39786
odv	venlafaxine	24	23	true	positive	Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.  		none	39786	none	39786
odv	venlafaxine	24	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.  		none	39786	none	39786
odv	venlafaxine	24	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.  		none	39786	none	39786
odv	venlafaxine	24	25	true	positive	Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.  Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  		none	39786	none	39786
odv	venlafaxine	24	25	true	positive	Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.  Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  		none	39786	none	39786
odv	venlafaxine	24	26	true	positive	Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.  Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  		none	39786	none	39786
odv	venlafaxine	24	26	true	positive	Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.  Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  		none	39786	none	39786
odv	venlafaxine	27	25	true	positive	Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  		none	39786	none	39786
odv	venlafaxine	27	25	true	positive	Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  		none	39786	none	39786
odv	venlafaxine	27	27	false	none	Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  		none	39786	none	39786
odv	venlafaxine	27	27	false	none	Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  		none	39786	none	39786
odv	venlafaxine	27	26	true	positive	Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  		none	39786	none	39786
odv	venlafaxine	27	26	true	positive	Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  		none	39786	none	39786
odv	venlafaxine	27	29	false	none	Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  		none	39786	none	39786
odv	venlafaxine	27	29	false	none	Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  		none	39786	none	39786
odv	venlafaxine	27	28	false	none	Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  		none	39786	none	39786
odv	venlafaxine	27	28	false	none	Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  		none	39786	none	39786
odv	venlafaxine	26	25	true	positive	Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  		none	39786	none	39786
odv	venlafaxine	26	25	true	positive	Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  		none	39786	none	39786
odv	venlafaxine	26	27	true	positive	Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  		none	39786	none	39786
odv	venlafaxine	26	27	true	positive	Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  		none	39786	none	39786
odv	venlafaxine	26	26	true	positive	Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  		none	39786	none	39786
odv	venlafaxine	26	26	true	positive	Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  		none	39786	none	39786
odv	venlafaxine	26	28	true	positive	Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  		none	39786	none	39786
odv	venlafaxine	26	28	true	positive	Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  		none	39786	none	39786
odv	Metoprolol	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		none	6918	none	D008790
odv	Metoprolol	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		none	6918	none	D008790
odv	Haloperidol	9	11	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		none	5093	none	D006220
odv	Haloperidol	9	11	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		none	5093	none	D006220
odv	Cimetidine	1	3	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		none	2541	none	2541
odv	Cimetidine	1	3	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		none	2541	none	2541
odv	Cimetidine	5	3	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		none	2541	none	2541
odv	Cimetidine	5	3	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		none	2541	none	2541
odv	Cimetidine	5	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		none	2541	none	2541
odv	Cimetidine	5	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		none	2541	none	2541
odv	Cimetidine	5	7	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		none	2541	none	2541
odv	Cimetidine	5	7	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		none	2541	none	2541
odv	Cimetidine	6	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		none	2541	none	2541
odv	Cimetidine	6	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		none	2541	none	2541
odv	Cimetidine	6	7	false	none	The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		none	2541	none	2541
odv	Cimetidine	6	7	false	none	The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		none	2541	none	2541
odv	Cimetidine	9	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		none	2541	none	2541
odv	Cimetidine	9	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		none	2541	none	2541
odv	metoprolol	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		none	6918	none	D008790
odv	metoprolol	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		none	6918	none	D008790
odv	p450	19	18	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		none	none	none	none
odv	p450	18	18	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		none	none	none	none
odv	p450	27	29	false	none	Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  		none	none	none	none
caffeine	Venlafaxine	51	51	true	negative	This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  		none	39786	none	39786
caffeine	Venlafaxine	51	51	true	negative	This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  		none	39786	none	39786
caffeine	Venlafaxine	51	50	true	negative	CYP1A2    Venlafaxine did not inhibit CYP1A2 in vitro.  This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  		none	39786	none	39786
caffeine	Venlafaxine	51	50	true	negative	CYP1A2    Venlafaxine did not inhibit CYP1A2 in vitro.  This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  		none	39786	none	39786
caffeine	Venlafaxine	51	53	false	none	This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  		none	39786	none	39786
caffeine	Venlafaxine	51	53	false	none	This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  		none	39786	none	39786
caffeine	Venlafaxine	51	52	true	negative	This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  		none	39786	none	39786
caffeine	Venlafaxine	51	52	true	negative	This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  		none	39786	none	39786
caffeine	tolbutamide	51	53	false	none	This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  		none	none	none	none
caffeine	venlafaxine	51	51	true	negative	This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  		none	39786	none	39786
caffeine	venlafaxine	51	51	true	negative	This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  		none	39786	none	39786
caffeine	venlafaxine	51	50	true	negative	CYP1A2    Venlafaxine did not inhibit CYP1A2 in vitro.  This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  		none	39786	none	39786
caffeine	venlafaxine	51	50	true	negative	CYP1A2    Venlafaxine did not inhibit CYP1A2 in vitro.  This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  		none	39786	none	39786
caffeine	venlafaxine	51	53	false	none	This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  		none	39786	none	39786
caffeine	venlafaxine	51	53	false	none	This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  		none	39786	none	39786
caffeine	venlafaxine	51	52	true	negative	This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  		none	39786	none	39786
caffeine	venlafaxine	51	52	true	negative	This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  		none	39786	none	39786
Ketoconazole	ketoconazole	22	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		D007654	D007654
Ketoconazole	Venlafaxine	22	21	false	none	Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		6135	39786	D007654	39786
Ketoconazole	Venlafaxine	22	21	false	none	Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		6135	39786	D007654	39786
Ketoconazole	Venlafaxine	22	23	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  		6135	39786	D007654	39786
Ketoconazole	Venlafaxine	22	23	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  		6135	39786	D007654	39786
Ketoconazole	Venlafaxine	22	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		6135	39786	D007654	39786
Ketoconazole	Venlafaxine	22	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		6135	39786	D007654	39786
Ketoconazole	venlafaxine	22	21	false	none	Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		6135	39786	D007654	39786
Ketoconazole	venlafaxine	22	21	false	none	Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		6135	39786	D007654	39786
Ketoconazole	venlafaxine	22	23	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  		6135	39786	D007654	39786
Ketoconazole	venlafaxine	22	23	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  		6135	39786	D007654	39786
Ketoconazole	venlafaxine	22	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		6135	39786	D007654	39786
Ketoconazole	venlafaxine	22	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		6135	39786	D007654	39786
cimetidine	diazepam	7	9	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		2541	3322	2541	D003975
cimetidine	diazepam	7	9	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		2541	3322	2541	D003975
cimetidine	alcohol	3	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		2541	none	2541	none
cimetidine	alcohol	3	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		2541	none	2541	none
cimetidine	Venlafaxine	3	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		2541	39786	2541	39786
cimetidine	Venlafaxine	3	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		2541	39786	2541	39786
cimetidine	Venlafaxine	3	2	false	none	Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		2541	39786	2541	39786
cimetidine	Venlafaxine	3	2	false	none	Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		2541	39786	2541	39786
cimetidine	Venlafaxine	3	3	true	positive	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		2541	39786	2541	39786
cimetidine	Venlafaxine	3	3	true	positive	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		2541	39786	2541	39786
cimetidine	Venlafaxine	3	4	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  		2541	39786	2541	39786
cimetidine	Venlafaxine	3	4	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  		2541	39786	2541	39786
cimetidine	Venlafaxine	3	5	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		2541	39786	2541	39786
cimetidine	Venlafaxine	3	5	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		2541	39786	2541	39786
cimetidine	Venlafaxine	5	3	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		2541	39786	2541	39786
cimetidine	Venlafaxine	5	3	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		2541	39786	2541	39786
cimetidine	Venlafaxine	5	4	false	none	The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		2541	39786	2541	39786
cimetidine	Venlafaxine	5	4	false	none	The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		2541	39786	2541	39786
cimetidine	Venlafaxine	5	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		2541	39786	2541	39786
cimetidine	Venlafaxine	5	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		2541	39786	2541	39786
cimetidine	Venlafaxine	5	6	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		2541	39786	2541	39786
cimetidine	Venlafaxine	5	6	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		2541	39786	2541	39786
cimetidine	Venlafaxine	5	7	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		2541	39786	2541	39786
cimetidine	Venlafaxine	5	7	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		2541	39786	2541	39786
cimetidine	Venlafaxine	7	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		2541	39786	2541	39786
cimetidine	Venlafaxine	7	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		2541	39786	2541	39786
cimetidine	Venlafaxine	7	6	false	none	The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		2541	39786	2541	39786
cimetidine	Venlafaxine	7	6	false	none	The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		2541	39786	2541	39786
cimetidine	Venlafaxine	7	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		2541	39786	2541	39786
cimetidine	Venlafaxine	7	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		2541	39786	2541	39786
cimetidine	Venlafaxine	7	9	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		2541	39786	2541	39786
cimetidine	Venlafaxine	7	9	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		2541	39786	2541	39786
cimetidine	ethanol	3	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		2541	448	2541	D000431
cimetidine	ethanol	3	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		2541	448	2541	D000431
cimetidine	ethanol	3	2	false	none	Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		2541	448	2541	D000431
cimetidine	ethanol	3	2	false	none	Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		2541	448	2541	D000431
cimetidine	venlafaxine	3	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		2541	39786	2541	39786
cimetidine	venlafaxine	3	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		2541	39786	2541	39786
cimetidine	venlafaxine	3	2	false	none	Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		2541	39786	2541	39786
cimetidine	venlafaxine	3	2	false	none	Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		2541	39786	2541	39786
cimetidine	venlafaxine	3	3	true	positive	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		2541	39786	2541	39786
cimetidine	venlafaxine	3	3	true	positive	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		2541	39786	2541	39786
cimetidine	venlafaxine	3	4	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  		2541	39786	2541	39786
cimetidine	venlafaxine	3	4	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  		2541	39786	2541	39786
cimetidine	venlafaxine	3	5	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		2541	39786	2541	39786
cimetidine	venlafaxine	3	5	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		2541	39786	2541	39786
cimetidine	venlafaxine	5	3	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		2541	39786	2541	39786
cimetidine	venlafaxine	5	3	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		2541	39786	2541	39786
cimetidine	venlafaxine	5	4	false	none	The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		2541	39786	2541	39786
cimetidine	venlafaxine	5	4	false	none	The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		2541	39786	2541	39786
cimetidine	venlafaxine	5	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		2541	39786	2541	39786
cimetidine	venlafaxine	5	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		2541	39786	2541	39786
cimetidine	venlafaxine	5	6	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		2541	39786	2541	39786
cimetidine	venlafaxine	5	6	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		2541	39786	2541	39786
cimetidine	venlafaxine	5	7	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		2541	39786	2541	39786
cimetidine	venlafaxine	5	7	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		2541	39786	2541	39786
cimetidine	venlafaxine	7	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		2541	39786	2541	39786
cimetidine	venlafaxine	7	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		2541	39786	2541	39786
cimetidine	venlafaxine	7	6	false	none	The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		2541	39786	2541	39786
cimetidine	venlafaxine	7	6	false	none	The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		2541	39786	2541	39786
cimetidine	venlafaxine	7	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		2541	39786	2541	39786
cimetidine	venlafaxine	7	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		2541	39786	2541	39786
cimetidine	venlafaxine	7	9	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		2541	39786	2541	39786
cimetidine	venlafaxine	7	9	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		2541	39786	2541	39786
cimetidine	Cimetidine	3	3	true	positive	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		2541	2541
cimetidine	Cimetidine	3	5	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		2541	2541
cimetidine	Cimetidine	5	3	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		2541	2541
cimetidine	Cimetidine	5	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		2541	2541
cimetidine	Cimetidine	5	7	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		2541	2541
cimetidine	Cimetidine	7	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		2541	2541
cimetidine	Cimetidine	7	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		2541	2541
Venlafaxine hydrochloride	Aspirin	67	65	false	none	These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	none	none	none
Venlafaxine hydrochloride	Aspirin	62	63	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
Venlafaxine hydrochloride	thromboplastin	68	70	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	none	none	none
Venlafaxine hydrochloride	Risperidone	42	43	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	none	none	none
Venlafaxine hydrochloride	Risperidone	42	44	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	none	none	none
Venlafaxine hydrochloride	warfarin	68	70	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	none	none	none
Venlafaxine hydrochloride	warfarin	68	66	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	none	none	none
Venlafaxine hydrochloride	warfarin	68	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	none	none	none
Venlafaxine hydrochloride	warfarin	67	66	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	none	none	none
Venlafaxine hydrochloride	warfarin	67	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	none	none	none
Venlafaxine hydrochloride	warfarin	62	63	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
Venlafaxine hydrochloride	prothrombin	68	70	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	none	none	none
Venlafaxine hydrochloride	Serotonin	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	none	none	none
Venlafaxine hydrochloride	Serotonin	59	61	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	none	none	none
Venlafaxine hydrochloride	Serotonin	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	none	none	none
Venlafaxine hydrochloride	Serotonin	62	64	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  		none	none	none	none
Venlafaxine hydrochloride	Serotonin	62	63	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
Venlafaxine hydrochloride	Serotonin	62	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	none	none	none
Venlafaxine hydrochloride	Serotonin	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	none	none	none
Venlafaxine hydrochloride	Serotonin	60	61	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	none	none	none
Venlafaxine hydrochloride	Venlafaxine	68	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	68	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	68	69	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	68	69	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	68	70	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	68	70	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	68	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	68	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	17	17	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	17	17	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	17	16	false	none	Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	17	16	false	none	Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	17	19	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	17	19	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	17	18	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	17	18	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	67	68	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	67	68	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	67	69	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	67	69	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	67	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	67	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	59	59	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	59	59	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	59	57	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	59	57	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	59	60	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	59	60	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	42	42	false	none	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	42	42	false	none	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	42	43	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	42	43	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	42	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	42	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	42	41	false	none	Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	42	41	false	none	Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	42	44	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	42	44	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	58	59	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	58	59	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	58	57	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	58	57	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	58	56	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	58	56	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	62	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	62	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	62	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	62	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	60	59	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	60	59	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	60	62	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	60	62	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	60	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	Venlafaxine	60	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	maoi	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	none	none	none
Venlafaxine hydrochloride	maoi	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	none	none	none
Venlafaxine hydrochloride	maoi	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	none	none	none
Venlafaxine hydrochloride	venlafaxine hydrochloride	68	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	68	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	68	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	68	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	17	17	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	17	17	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	67	68	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	67	68	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	67	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	67	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	59	59	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	59	59	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	59	60	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	59	60	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	42	42	false	none	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	42	42	false	none	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	58	59	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	58	59	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	62	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	62	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	62	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	62	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	60	59	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	60	59	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	60	62	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	60	62	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	60	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Venlafaxine hydrochloride	venlafaxine hydrochloride	60	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Venlafaxine hydrochloride	aspirin	67	65	false	none	These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	none	none	none
Venlafaxine hydrochloride	aspirin	62	63	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
Venlafaxine hydrochloride	risperidone	42	43	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	none	none	none
Venlafaxine hydrochloride	risperidone	42	44	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	none	none	none
Venlafaxine hydrochloride	serotonin	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	none	none	none
Venlafaxine hydrochloride	serotonin	59	61	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	none	none	none
Venlafaxine hydrochloride	serotonin	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	none	none	none
Venlafaxine hydrochloride	serotonin	62	64	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  		none	none	none	none
Venlafaxine hydrochloride	serotonin	62	63	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
Venlafaxine hydrochloride	serotonin	62	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	none	none	none
Venlafaxine hydrochloride	serotonin	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	none	none	none
Venlafaxine hydrochloride	serotonin	60	61	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	none	none	none
Venlafaxine hydrochloride	linezolid	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	none	none	none
Venlafaxine hydrochloride	linezolid	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	none	none	none
Venlafaxine hydrochloride	linezolid	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	none	none	none
Venlafaxine hydrochloride	tramadol	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	none	none	none
Venlafaxine hydrochloride	tramadol	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	none	none	none
Venlafaxine hydrochloride	tramadol	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	none	none	none
Venlafaxine hydrochloride	venlafaxine	68	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	68	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	68	69	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	68	69	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	68	70	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	68	70	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	68	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	68	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	17	17	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	17	17	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	17	16	false	none	Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	17	16	false	none	Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	17	19	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	17	19	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	17	18	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	17	18	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	67	68	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	67	68	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	67	69	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	67	69	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	67	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	67	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	59	59	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	59	59	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	59	57	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	59	57	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	59	60	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	59	60	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	42	42	false	none	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	42	42	false	none	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	42	43	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	42	43	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	42	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	42	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	42	41	false	none	Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	42	41	false	none	Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	42	44	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	42	44	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	58	59	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	58	59	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	58	57	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	58	57	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	58	56	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	58	56	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	62	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	62	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	62	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	62	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	60	59	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	60	59	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	60	62	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	60	62	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	60	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	venlafaxine	60	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Venlafaxine hydrochloride	tryptophan	59	60	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	none	none	none
Venlafaxine hydrochloride	tryptophan	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	none	none	none
Venlafaxine hydrochloride	tryptophan	62	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	none	none	none
Venlafaxine hydrochloride	tryptophan	60	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	none	none	none
Venlafaxine hydrochloride	Metoprolol	42	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		none	6918	none	D008790
Venlafaxine hydrochloride	Metoprolol	42	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		none	6918	none	D008790
Venlafaxine hydrochloride	9-hydroxyrisperidone	42	43	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	none	none	none
Venlafaxine hydrochloride	9-hydroxyrisperidone	42	44	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	none	none	none
Venlafaxine hydrochloride	clozapine	68	69	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		none	none	none	none
Venlafaxine hydrochloride	clozapine	67	69	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		none	none	none	none
Venlafaxine hydrochloride	metoprolol	42	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		none	6918	none	D008790
Venlafaxine hydrochloride	metoprolol	42	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		none	6918	none	D008790
Venlafaxine hydrochloride	p450	17	18	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		none	none	none	none
Venlafaxine hydrochloride	triptan	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	none	none	none
Venlafaxine hydrochloride	triptan	59	61	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	none	none	none
Venlafaxine hydrochloride	triptan	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	none	none	none
Venlafaxine hydrochloride	triptan	62	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	none	none	none
Venlafaxine hydrochloride	triptan	62	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	none	none	none
Venlafaxine hydrochloride	triptan	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	none	none	none
Venlafaxine hydrochloride	triptan	60	62	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	none	none	none
Venlafaxine hydrochloride	triptan	60	61	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	none	none	none
Aspirin	warfarin	65	66	false	none	These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  		none	none	none	none
Aspirin	warfarin	65	67	false	none	These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	none	none	none
Aspirin	warfarin	65	63	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  		none	none	none	none
Aspirin	warfarin	63	63	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
Aspirin	Serotonin	65	64	false	none	Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  		none	none	none	none
Aspirin	Serotonin	65	63	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  		none	none	none	none
Aspirin	Serotonin	63	64	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  		none	none	none	none
Aspirin	Serotonin	63	63	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
Aspirin	Serotonin	63	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
Aspirin	Venlafaxine	65	67	false	none	These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	39786
Aspirin	Venlafaxine	65	67	false	none	These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	39786
Aspirin	Venlafaxine	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	39786	none	39786
Aspirin	Venlafaxine	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	39786	none	39786
Aspirin	venlafaxine hydrochloride	65	67	false	none	These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	C047426
Aspirin	venlafaxine hydrochloride	65	67	false	none	These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	C047426
Aspirin	venlafaxine hydrochloride	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	39786	none	C047426
Aspirin	venlafaxine hydrochloride	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	39786	none	C047426
Aspirin	aspirin	65	65	false	none	These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  		none	none	none	none
Aspirin	aspirin	65	63	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  		none	none	none	none
Aspirin	aspirin	63	65	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  		none	none	none	none
Aspirin	aspirin	63	63	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
Aspirin	serotonin	65	64	false	none	Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  		none	none	none	none
Aspirin	serotonin	65	63	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  		none	none	none	none
Aspirin	serotonin	63	64	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  		none	none	none	none
Aspirin	serotonin	63	63	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
Aspirin	serotonin	63	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
Aspirin	venlafaxine	65	67	false	none	These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	39786
Aspirin	venlafaxine	65	67	false	none	These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	39786
Aspirin	venlafaxine	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	39786	none	39786
Aspirin	venlafaxine	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	39786	none	39786
Aspirin	triptan	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
Aspirin	triptan	63	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
diazepam	Risperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	none	D003975	none
diazepam	Risperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	none	D003975	none
diazepam	alprazolam	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	none	D003975	none
diazepam	alprazolam	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	none	D003975	none
diazepam	Indinavir	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		3322	none	D003975	none
diazepam	Indinavir	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		3322	none	D003975	none
diazepam	Indinavir	46	47	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		3322	none	D003975	none
diazepam	Indinavir	46	47	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		3322	none	D003975	none
diazepam	Venlafaxine	54	54	true	negative	CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		3322	39786	D003975	39786
diazepam	Venlafaxine	54	54	true	negative	CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		3322	39786	D003975	39786
diazepam	Venlafaxine	54	53	false	none	In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		3322	39786	D003975	39786
diazepam	Venlafaxine	54	53	false	none	In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		3322	39786	D003975	39786
diazepam	Venlafaxine	54	52	false	none	CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		3322	39786	D003975	39786
diazepam	Venlafaxine	54	52	false	none	CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		3322	39786	D003975	39786
diazepam	Venlafaxine	54	56	false	none	CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  7.9 Monoamine Oxidase Inhibitors    See Contraindications (4) and Warnings and Precautions (5.2).  7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  		3322	39786	D003975	39786
diazepam	Venlafaxine	54	56	false	none	CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  7.9 Monoamine Oxidase Inhibitors    See Contraindications (4) and Warnings and Precautions (5.2).  7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  		3322	39786	D003975	39786
diazepam	Venlafaxine	9	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		3322	39786	D003975	39786
diazepam	Venlafaxine	9	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		3322	39786	D003975	39786
diazepam	Venlafaxine	9	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		3322	39786	D003975	39786
diazepam	Venlafaxine	9	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		3322	39786	D003975	39786
diazepam	Venlafaxine	9	10	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	39786	D003975	39786
diazepam	Venlafaxine	9	10	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	39786	D003975	39786
diazepam	Venlafaxine	9	11	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3322	39786	D003975	39786
diazepam	Venlafaxine	9	11	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3322	39786	D003975	39786
diazepam	Venlafaxine	10	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	39786	D003975	39786
diazepam	Venlafaxine	10	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	39786	D003975	39786
diazepam	Venlafaxine	10	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	39786	D003975	39786
diazepam	Venlafaxine	10	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	39786	D003975	39786
diazepam	Venlafaxine	10	11	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3322	39786	D003975	39786
diazepam	Venlafaxine	10	11	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3322	39786	D003975	39786
diazepam	Venlafaxine	10	12	true	negative	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		3322	39786	D003975	39786
diazepam	Venlafaxine	10	12	true	negative	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		3322	39786	D003975	39786
diazepam	Venlafaxine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	39786	D003975	39786
diazepam	Venlafaxine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	39786	D003975	39786
diazepam	Venlafaxine	46	47	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		3322	39786	D003975	39786
diazepam	Venlafaxine	46	47	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		3322	39786	D003975	39786
diazepam	Venlafaxine	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	39786	D003975	39786
diazepam	Venlafaxine	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	39786	D003975	39786
diazepam	Venlafaxine	46	45	true	negative	CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	39786	D003975	39786
diazepam	Venlafaxine	46	45	true	negative	CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	39786	D003975	39786
diazepam	Venlafaxine	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		3322	39786	D003975	39786
diazepam	Venlafaxine	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		3322	39786	D003975	39786
diazepam	risperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	none	D003975	none
diazepam	risperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	none	D003975	none
diazepam	terfenadine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	none	D003975	none
diazepam	terfenadine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	none	D003975	none
diazepam	tolbutamide	54	53	false	none	In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		3322	none	D003975	none
diazepam	tolbutamide	54	53	false	none	In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		3322	none	D003975	none
diazepam	desmethyldiazepam	9	10	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	3155	D003975	D003708
diazepam	desmethyldiazepam	9	10	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	3155	D003975	D003708
diazepam	desmethyldiazepam	10	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	3155	D003975	D003708
diazepam	desmethyldiazepam	10	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	3155	D003975	D003708
diazepam	indinavir	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		3322	none	D003975	none
diazepam	indinavir	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		3322	none	D003975	none
diazepam	indinavir	46	47	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		3322	none	D003975	none
diazepam	indinavir	46	47	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		3322	none	D003975	none
diazepam	venlafaxine	54	54	true	negative	CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		3322	39786	D003975	39786
diazepam	venlafaxine	54	54	true	negative	CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		3322	39786	D003975	39786
diazepam	venlafaxine	54	53	false	none	In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		3322	39786	D003975	39786
diazepam	venlafaxine	54	53	false	none	In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		3322	39786	D003975	39786
diazepam	venlafaxine	54	52	false	none	CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		3322	39786	D003975	39786
diazepam	venlafaxine	54	52	false	none	CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		3322	39786	D003975	39786
diazepam	venlafaxine	54	56	false	none	CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  7.9 Monoamine Oxidase Inhibitors    See Contraindications (4) and Warnings and Precautions (5.2).  7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  		3322	39786	D003975	39786
diazepam	venlafaxine	54	56	false	none	CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  7.9 Monoamine Oxidase Inhibitors    See Contraindications (4) and Warnings and Precautions (5.2).  7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  		3322	39786	D003975	39786
diazepam	venlafaxine	9	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		3322	39786	D003975	39786
diazepam	venlafaxine	9	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		3322	39786	D003975	39786
diazepam	venlafaxine	9	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		3322	39786	D003975	39786
diazepam	venlafaxine	9	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		3322	39786	D003975	39786
diazepam	venlafaxine	9	10	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	39786	D003975	39786
diazepam	venlafaxine	9	10	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	39786	D003975	39786
diazepam	venlafaxine	9	11	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3322	39786	D003975	39786
diazepam	venlafaxine	9	11	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3322	39786	D003975	39786
diazepam	venlafaxine	10	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	39786	D003975	39786
diazepam	venlafaxine	10	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	39786	D003975	39786
diazepam	venlafaxine	10	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	39786	D003975	39786
diazepam	venlafaxine	10	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3322	39786	D003975	39786
diazepam	venlafaxine	10	11	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3322	39786	D003975	39786
diazepam	venlafaxine	10	11	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3322	39786	D003975	39786
diazepam	venlafaxine	10	12	true	negative	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		3322	39786	D003975	39786
diazepam	venlafaxine	10	12	true	negative	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		3322	39786	D003975	39786
diazepam	venlafaxine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	39786	D003975	39786
diazepam	venlafaxine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	39786	D003975	39786
diazepam	venlafaxine	46	47	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		3322	39786	D003975	39786
diazepam	venlafaxine	46	47	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		3322	39786	D003975	39786
diazepam	venlafaxine	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	39786	D003975	39786
diazepam	venlafaxine	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	39786	D003975	39786
diazepam	venlafaxine	46	45	true	negative	CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	39786	D003975	39786
diazepam	venlafaxine	46	45	true	negative	CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	39786	D003975	39786
diazepam	venlafaxine	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		3322	39786	D003975	39786
diazepam	venlafaxine	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		3322	39786	D003975	39786
diazepam	Haloperidol	9	11	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3322	5093	D003975	D006220
diazepam	Haloperidol	9	11	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3322	5093	D003975	D006220
diazepam	Haloperidol	10	11	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3322	5093	D003975	D006220
diazepam	Haloperidol	10	11	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3322	5093	D003975	D006220
diazepam	Haloperidol	10	12	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		3322	5093	D003975	D006220
diazepam	Haloperidol	10	12	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		3322	5093	D003975	D006220
diazepam	9-hydroxyrisperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	none	D003975	none
diazepam	9-hydroxyrisperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		3322	none	D003975	none
diazepam	Cimetidine	9	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		3322	2541	D003975	2541
diazepam	Cimetidine	9	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		3322	2541	D003975	2541
alcohol	Venlafaxine	1	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  		none	39786	none	39786
alcohol	Venlafaxine	1	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  		none	39786	none	39786
alcohol	Venlafaxine	1	2	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  		none	39786	none	39786
alcohol	Venlafaxine	1	2	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  		none	39786	none	39786
alcohol	Venlafaxine	1	3	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		none	39786	none	39786
alcohol	Venlafaxine	1	3	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		none	39786	none	39786
alcohol	ethanol	1	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  		none	448	none	D000431
alcohol	ethanol	1	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  		none	448	none	D000431
alcohol	ethanol	1	2	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  		none	448	none	D000431
alcohol	ethanol	1	2	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  		none	448	none	D000431
alcohol	venlafaxine	1	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  		none	39786	none	39786
alcohol	venlafaxine	1	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  		none	39786	none	39786
alcohol	venlafaxine	1	2	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  		none	39786	none	39786
alcohol	venlafaxine	1	2	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  		none	39786	none	39786
alcohol	venlafaxine	1	3	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		none	39786	none	39786
alcohol	venlafaxine	1	3	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		none	39786	none	39786
alcohol	Cimetidine	1	3	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		none	2541	none	2541
alcohol	Cimetidine	1	3	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		none	2541	none	2541
thromboplastin	warfarin	70	70	false	none	There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	none	none	none
thromboplastin	prothrombin	70	70	false	none	There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	none	none	none
thromboplastin	Venlafaxine	70	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
thromboplastin	Venlafaxine	70	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
thromboplastin	Venlafaxine	70	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
thromboplastin	Venlafaxine	70	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
thromboplastin	Venlafaxine	70	70	false	none	There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
thromboplastin	Venlafaxine	70	70	false	none	There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
thromboplastin	venlafaxine hydrochloride	70	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	C047426
thromboplastin	venlafaxine hydrochloride	70	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	C047426
thromboplastin	venlafaxine	70	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
thromboplastin	venlafaxine	70	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
thromboplastin	venlafaxine	70	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
thromboplastin	venlafaxine	70	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
thromboplastin	venlafaxine	70	70	false	none	There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
thromboplastin	venlafaxine	70	70	false	none	There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
thromboplastin	clozapine	70	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	none	none	none
dextrorphan	imipramine	30	31	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		none	5691	D003917	5691
dextrorphan	imipramine	30	31	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		none	5691	D003917	5691
dextrorphan	Venlafaxine	30	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		none	39786	D003917	39786
dextrorphan	Venlafaxine	30	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		none	39786	D003917	39786
dextrorphan	Venlafaxine	30	28	false	none	Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		none	39786	D003917	39786
dextrorphan	Venlafaxine	30	28	false	none	Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		none	39786	D003917	39786
dextrorphan	Venlafaxine	30	31	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		none	39786	D003917	39786
dextrorphan	Venlafaxine	30	31	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		none	39786	D003917	39786
dextrorphan	Venlafaxine	30	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		none	39786	D003917	39786
dextrorphan	Venlafaxine	30	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		none	39786	D003917	39786
dextrorphan	Venlafaxine	30	32	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		none	39786	D003917	39786
dextrorphan	Venlafaxine	30	32	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		none	39786	D003917	39786
dextrorphan	fluoxetine	30	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		none	4493	D003917	D005473
dextrorphan	fluoxetine	30	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		none	4493	D003917	D005473
dextrorphan	desipramine	30	32	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		none	3247	D003917	3247
dextrorphan	desipramine	30	32	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		none	3247	D003917	3247
dextrorphan	venlafaxine	30	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		none	39786	D003917	39786
dextrorphan	venlafaxine	30	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		none	39786	D003917	39786
dextrorphan	venlafaxine	30	28	false	none	Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		none	39786	D003917	39786
dextrorphan	venlafaxine	30	28	false	none	Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		none	39786	D003917	39786
dextrorphan	venlafaxine	30	31	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		none	39786	D003917	39786
dextrorphan	venlafaxine	30	31	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		none	39786	D003917	39786
dextrorphan	venlafaxine	30	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		none	39786	D003917	39786
dextrorphan	venlafaxine	30	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		none	39786	D003917	39786
dextrorphan	venlafaxine	30	32	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		none	39786	D003917	39786
dextrorphan	venlafaxine	30	32	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		none	39786	D003917	39786
dextrorphan	dextromethorphan	30	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		none	0	D003917	D003915
dextrorphan	dextromethorphan	30	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		none	0	D003917	D003915
dextrorphan	p450	30	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		none	none	D003917	none
Risperidone	alprazolam	44	46	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	none	none	none
Risperidone	Venlafaxine	43	42	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	39786	none	39786
Risperidone	Venlafaxine	43	42	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	39786	none	39786
Risperidone	Venlafaxine	43	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	39786	none	39786
Risperidone	Venlafaxine	43	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	39786	none	39786
Risperidone	Venlafaxine	43	41	true	positive	Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	39786	none	39786
Risperidone	Venlafaxine	43	41	true	positive	Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	39786	none	39786
Risperidone	Venlafaxine	43	44	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	39786
Risperidone	Venlafaxine	43	44	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	39786
Risperidone	Venlafaxine	43	45	true	negative	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  		none	39786	none	39786
Risperidone	Venlafaxine	43	45	true	negative	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  		none	39786	none	39786
Risperidone	Venlafaxine	44	42	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	39786
Risperidone	Venlafaxine	44	42	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	39786
Risperidone	Venlafaxine	44	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	39786
Risperidone	Venlafaxine	44	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	39786
Risperidone	Venlafaxine	44	46	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	39786	none	39786
Risperidone	Venlafaxine	44	46	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	39786	none	39786
Risperidone	Venlafaxine	44	44	false	none	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	39786
Risperidone	Venlafaxine	44	44	false	none	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	39786
Risperidone	Venlafaxine	44	45	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  		none	39786	none	39786
Risperidone	Venlafaxine	44	45	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  		none	39786	none	39786
Risperidone	venlafaxine hydrochloride	43	42	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	39786	none	C047426
Risperidone	venlafaxine hydrochloride	43	42	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	39786	none	C047426
Risperidone	venlafaxine hydrochloride	44	42	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	C047426
Risperidone	venlafaxine hydrochloride	44	42	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	C047426
Risperidone	risperidone	43	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	none	none	none
Risperidone	risperidone	43	44	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	none	none	none
Risperidone	risperidone	44	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	none	none	none
Risperidone	risperidone	44	44	false	none	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	none	none	none
Risperidone	terfenadine	44	46	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	none	none	none
Risperidone	venlafaxine	43	42	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	39786	none	39786
Risperidone	venlafaxine	43	42	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	39786	none	39786
Risperidone	venlafaxine	43	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	39786	none	39786
Risperidone	venlafaxine	43	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	39786	none	39786
Risperidone	venlafaxine	43	41	true	positive	Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	39786	none	39786
Risperidone	venlafaxine	43	41	true	positive	Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	39786	none	39786
Risperidone	venlafaxine	43	44	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	39786
Risperidone	venlafaxine	43	44	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	39786
Risperidone	venlafaxine	43	45	true	negative	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  		none	39786	none	39786
Risperidone	venlafaxine	43	45	true	negative	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  		none	39786	none	39786
Risperidone	venlafaxine	44	42	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	39786
Risperidone	venlafaxine	44	42	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	39786
Risperidone	venlafaxine	44	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	39786
Risperidone	venlafaxine	44	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	39786
Risperidone	venlafaxine	44	46	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	39786	none	39786
Risperidone	venlafaxine	44	46	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	39786	none	39786
Risperidone	venlafaxine	44	44	false	none	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	39786
Risperidone	venlafaxine	44	44	false	none	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	39786
Risperidone	venlafaxine	44	45	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  		none	39786	none	39786
Risperidone	venlafaxine	44	45	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  		none	39786	none	39786
Risperidone	9-hydroxyrisperidone	43	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	none	none	none
Risperidone	9-hydroxyrisperidone	43	44	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	none	none	none
Risperidone	9-hydroxyrisperidone	44	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	none	none	none
Risperidone	9-hydroxyrisperidone	44	44	false	none	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	none	none	none
warfarin	prothrombin	70	70	false	none	There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	none	none	none
warfarin	Serotonin	66	64	false	none	Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  		none	none	none	none
warfarin	Serotonin	63	64	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  		none	none	none	none
warfarin	Serotonin	63	63	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
warfarin	Serotonin	63	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
warfarin	Venlafaxine	70	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
warfarin	Venlafaxine	70	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
warfarin	Venlafaxine	70	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
warfarin	Venlafaxine	70	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
warfarin	Venlafaxine	70	70	false	none	There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
warfarin	Venlafaxine	70	70	false	none	There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
warfarin	Venlafaxine	66	68	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	39786
warfarin	Venlafaxine	66	68	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	39786
warfarin	Venlafaxine	66	67	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	39786
warfarin	Venlafaxine	66	67	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	39786
warfarin	Venlafaxine	67	68	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	39786
warfarin	Venlafaxine	67	68	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	39786
warfarin	Venlafaxine	67	69	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		none	39786	none	39786
warfarin	Venlafaxine	67	69	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		none	39786	none	39786
warfarin	Venlafaxine	67	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	39786
warfarin	Venlafaxine	67	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	39786
warfarin	Venlafaxine	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	39786	none	39786
warfarin	Venlafaxine	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	39786	none	39786
warfarin	venlafaxine hydrochloride	70	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	C047426
warfarin	venlafaxine hydrochloride	70	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	C047426
warfarin	venlafaxine hydrochloride	66	68	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	C047426
warfarin	venlafaxine hydrochloride	66	68	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	C047426
warfarin	venlafaxine hydrochloride	66	67	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	C047426
warfarin	venlafaxine hydrochloride	66	67	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	C047426
warfarin	venlafaxine hydrochloride	67	68	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	C047426
warfarin	venlafaxine hydrochloride	67	68	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	C047426
warfarin	venlafaxine hydrochloride	67	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	C047426
warfarin	venlafaxine hydrochloride	67	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	C047426
warfarin	venlafaxine hydrochloride	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	39786	none	C047426
warfarin	venlafaxine hydrochloride	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	39786	none	C047426
warfarin	aspirin	66	65	false	none	These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  		none	none	none	none
warfarin	aspirin	67	65	false	none	These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	none	none	none
warfarin	aspirin	63	65	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  		none	none	none	none
warfarin	aspirin	63	63	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
warfarin	serotonin	66	64	false	none	Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  		none	none	none	none
warfarin	serotonin	63	64	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  		none	none	none	none
warfarin	serotonin	63	63	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
warfarin	serotonin	63	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
warfarin	venlafaxine	70	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
warfarin	venlafaxine	70	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
warfarin	venlafaxine	70	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
warfarin	venlafaxine	70	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
warfarin	venlafaxine	70	70	false	none	There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
warfarin	venlafaxine	70	70	false	none	There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
warfarin	venlafaxine	66	68	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	39786
warfarin	venlafaxine	66	68	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	39786
warfarin	venlafaxine	66	67	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	39786
warfarin	venlafaxine	66	67	false	none	Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	39786
warfarin	venlafaxine	67	68	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	39786
warfarin	venlafaxine	67	68	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		none	39786	none	39786
warfarin	venlafaxine	67	69	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		none	39786	none	39786
warfarin	venlafaxine	67	69	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		none	39786	none	39786
warfarin	venlafaxine	67	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	39786
warfarin	venlafaxine	67	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	39786
warfarin	venlafaxine	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	39786	none	39786
warfarin	venlafaxine	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	39786	none	39786
warfarin	clozapine	70	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	none	none	none
warfarin	clozapine	67	69	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		none	none	none	none
warfarin	triptan	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
warfarin	triptan	63	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
imipramine	Venlafaxine	34	34	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	39786	5691	39786
imipramine	Venlafaxine	34	34	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	39786	5691	39786
imipramine	Venlafaxine	34	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	39786	5691	39786
imipramine	Venlafaxine	34	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	39786	5691	39786
imipramine	Venlafaxine	34	33	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	39786	5691	39786
imipramine	Venlafaxine	34	33	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	39786	5691	39786
imipramine	Venlafaxine	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		5691	39786	5691	39786
imipramine	Venlafaxine	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		5691	39786	5691	39786
imipramine	Venlafaxine	31	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	39786	5691	39786
imipramine	Venlafaxine	31	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	39786	5691	39786
imipramine	Venlafaxine	31	31	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	39786	5691	39786
imipramine	Venlafaxine	31	31	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	39786	5691	39786
imipramine	Venlafaxine	31	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	39786	5691	39786
imipramine	Venlafaxine	31	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	39786	5691	39786
imipramine	Venlafaxine	31	32	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		5691	39786	5691	39786
imipramine	Venlafaxine	31	32	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		5691	39786	5691	39786
imipramine	Venlafaxine	31	33	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		5691	39786	5691	39786
imipramine	Venlafaxine	31	33	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		5691	39786	5691	39786
imipramine	fluoxetine	31	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	4493	5691	D005473
imipramine	fluoxetine	31	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	4493	5691	D005473
imipramine	desipramine	34	35	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  		5691	3247	5691	3247
imipramine	desipramine	34	35	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  		5691	3247	5691	3247
imipramine	desipramine	34	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	3247	5691	3247
imipramine	desipramine	34	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	3247	5691	3247
imipramine	desipramine	34	33	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	3247	5691	3247
imipramine	desipramine	34	33	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	3247	5691	3247
imipramine	desipramine	31	32	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		5691	3247	5691	3247
imipramine	desipramine	31	32	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		5691	3247	5691	3247
imipramine	desipramine	31	33	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		5691	3247	5691	3247
imipramine	desipramine	31	33	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		5691	3247	5691	3247
imipramine	venlafaxine	34	34	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	39786	5691	39786
imipramine	venlafaxine	34	34	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	39786	5691	39786
imipramine	venlafaxine	34	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	39786	5691	39786
imipramine	venlafaxine	34	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	39786	5691	39786
imipramine	venlafaxine	34	33	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	39786	5691	39786
imipramine	venlafaxine	34	33	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		5691	39786	5691	39786
imipramine	venlafaxine	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		5691	39786	5691	39786
imipramine	venlafaxine	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		5691	39786	5691	39786
imipramine	venlafaxine	31	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	39786	5691	39786
imipramine	venlafaxine	31	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	39786	5691	39786
imipramine	venlafaxine	31	31	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	39786	5691	39786
imipramine	venlafaxine	31	31	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	39786	5691	39786
imipramine	venlafaxine	31	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	39786	5691	39786
imipramine	venlafaxine	31	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	39786	5691	39786
imipramine	venlafaxine	31	32	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		5691	39786	5691	39786
imipramine	venlafaxine	31	32	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		5691	39786	5691	39786
imipramine	venlafaxine	31	33	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		5691	39786	5691	39786
imipramine	venlafaxine	31	33	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		5691	39786	5691	39786
imipramine	Metoprolol	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		5691	6918	5691	D008790
imipramine	Metoprolol	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		5691	6918	5691	D008790
imipramine	dextromethorphan	31	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	0	5691	D003915
imipramine	dextromethorphan	31	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	0	5691	D003915
imipramine	metoprolol	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		5691	6918	5691	D008790
imipramine	metoprolol	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		5691	6918	5691	D008790
imipramine	p450	31	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	none	5691	none
imipramine	p450	31	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		5691	none	5691	none
prothrombin	Venlafaxine	70	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
prothrombin	Venlafaxine	70	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
prothrombin	Venlafaxine	70	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
prothrombin	Venlafaxine	70	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
prothrombin	Venlafaxine	70	70	false	none	There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
prothrombin	Venlafaxine	70	70	false	none	There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
prothrombin	venlafaxine hydrochloride	70	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	C047426
prothrombin	venlafaxine hydrochloride	70	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	C047426
prothrombin	venlafaxine	70	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
prothrombin	venlafaxine	70	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
prothrombin	venlafaxine	70	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
prothrombin	venlafaxine	70	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
prothrombin	venlafaxine	70	70	false	none	There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
prothrombin	venlafaxine	70	70	false	none	There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	39786	none	39786
prothrombin	clozapine	70	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		none	none	none	none
Serotonin	Venlafaxine	64	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  		none	39786	none	39786
Serotonin	Venlafaxine	64	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  		none	39786	none	39786
Serotonin	Venlafaxine	58	59	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Serotonin	Venlafaxine	58	59	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Serotonin	Venlafaxine	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Serotonin	Venlafaxine	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Serotonin	Venlafaxine	58	57	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Serotonin	Venlafaxine	58	57	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Serotonin	Venlafaxine	58	56	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Serotonin	Venlafaxine	58	56	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Serotonin	Venlafaxine	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Serotonin	Venlafaxine	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Serotonin	Venlafaxine	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	39786	none	39786
Serotonin	Venlafaxine	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	39786	none	39786
Serotonin	Venlafaxine	61	59	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	39786	none	39786
Serotonin	Venlafaxine	61	59	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	39786	none	39786
Serotonin	Venlafaxine	61	62	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Serotonin	Venlafaxine	61	62	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Serotonin	Venlafaxine	61	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	39786	none	39786
Serotonin	Venlafaxine	61	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	39786	none	39786
Serotonin	maoi	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	none	none	none
Serotonin	venlafaxine hydrochloride	64	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  		none	39786	none	C047426
Serotonin	venlafaxine hydrochloride	64	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  		none	39786	none	C047426
Serotonin	venlafaxine hydrochloride	58	59	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Serotonin	venlafaxine hydrochloride	58	59	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Serotonin	venlafaxine hydrochloride	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Serotonin	venlafaxine hydrochloride	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Serotonin	venlafaxine hydrochloride	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Serotonin	venlafaxine hydrochloride	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Serotonin	venlafaxine hydrochloride	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	39786	none	C047426
Serotonin	venlafaxine hydrochloride	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	39786	none	C047426
Serotonin	venlafaxine hydrochloride	61	59	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	39786	none	C047426
Serotonin	venlafaxine hydrochloride	61	59	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	39786	none	C047426
Serotonin	venlafaxine hydrochloride	61	62	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Serotonin	venlafaxine hydrochloride	61	62	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
Serotonin	venlafaxine hydrochloride	61	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	39786	none	C047426
Serotonin	venlafaxine hydrochloride	61	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	39786	none	C047426
Serotonin	aspirin	64	65	false	none	Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  		none	none	none	none
Serotonin	aspirin	64	63	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  		none	none	none	none
Serotonin	aspirin	63	65	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  		none	none	none	none
Serotonin	aspirin	63	63	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
Serotonin	aspirin	61	63	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
Serotonin	serotonin	64	64	false	none	Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  		none	none	none	none
Serotonin	serotonin	64	63	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  		none	none	none	none
Serotonin	serotonin	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	none	none	none
Serotonin	serotonin	63	64	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  		none	none	none	none
Serotonin	serotonin	63	63	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
Serotonin	serotonin	63	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
Serotonin	serotonin	61	63	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
Serotonin	serotonin	61	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	none	none	none
Serotonin	linezolid	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	none	none	none
Serotonin	tramadol	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	none	none	none
Serotonin	venlafaxine	64	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  		none	39786	none	39786
Serotonin	venlafaxine	64	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  		none	39786	none	39786
Serotonin	venlafaxine	58	59	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Serotonin	venlafaxine	58	59	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Serotonin	venlafaxine	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Serotonin	venlafaxine	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Serotonin	venlafaxine	58	57	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Serotonin	venlafaxine	58	57	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Serotonin	venlafaxine	58	56	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Serotonin	venlafaxine	58	56	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Serotonin	venlafaxine	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Serotonin	venlafaxine	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Serotonin	venlafaxine	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	39786	none	39786
Serotonin	venlafaxine	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	39786	none	39786
Serotonin	venlafaxine	61	59	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	39786	none	39786
Serotonin	venlafaxine	61	59	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	39786	none	39786
Serotonin	venlafaxine	61	62	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Serotonin	venlafaxine	61	62	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
Serotonin	venlafaxine	61	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	39786	none	39786
Serotonin	venlafaxine	61	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	39786	none	39786
Serotonin	tryptophan	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	none	none	none
Serotonin	tryptophan	61	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	none	none	none
Serotonin	triptan	64	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  		none	none	none	none
Serotonin	triptan	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	none	none	none
Serotonin	triptan	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
Serotonin	triptan	63	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
Serotonin	triptan	61	62	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	none	none	none
Serotonin	triptan	61	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	none	none	none
alprazolam	Indinavir	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	none	none	none
alprazolam	Indinavir	46	47	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		none	none	none	none
alprazolam	Venlafaxine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	39786	none	39786
alprazolam	Venlafaxine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	39786	none	39786
alprazolam	Venlafaxine	46	47	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		none	39786	none	39786
alprazolam	Venlafaxine	46	47	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		none	39786	none	39786
alprazolam	Venlafaxine	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	39786	none	39786
alprazolam	Venlafaxine	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	39786	none	39786
alprazolam	Venlafaxine	46	45	true	negative	CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	39786	none	39786
alprazolam	Venlafaxine	46	45	true	negative	CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	39786	none	39786
alprazolam	Venlafaxine	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
alprazolam	Venlafaxine	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
alprazolam	risperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	none	none	none
alprazolam	terfenadine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	none	none	none
alprazolam	indinavir	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	none	none	none
alprazolam	indinavir	46	47	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		none	none	none	none
alprazolam	venlafaxine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	39786	none	39786
alprazolam	venlafaxine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	39786	none	39786
alprazolam	venlafaxine	46	47	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		none	39786	none	39786
alprazolam	venlafaxine	46	47	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		none	39786	none	39786
alprazolam	venlafaxine	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	39786	none	39786
alprazolam	venlafaxine	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	39786	none	39786
alprazolam	venlafaxine	46	45	true	negative	CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	39786	none	39786
alprazolam	venlafaxine	46	45	true	negative	CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	39786	none	39786
alprazolam	venlafaxine	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
alprazolam	venlafaxine	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
alprazolam	9-hydroxyrisperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	none	none	none
ketoconazole	Venlafaxine	22	21	false	none	Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		6135	39786	D007654	39786
ketoconazole	Venlafaxine	22	21	false	none	Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		6135	39786	D007654	39786
ketoconazole	Venlafaxine	22	23	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  		6135	39786	D007654	39786
ketoconazole	Venlafaxine	22	23	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  		6135	39786	D007654	39786
ketoconazole	Venlafaxine	22	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		6135	39786	D007654	39786
ketoconazole	Venlafaxine	22	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		6135	39786	D007654	39786
ketoconazole	venlafaxine	22	21	false	none	Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		6135	39786	D007654	39786
ketoconazole	venlafaxine	22	21	false	none	Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		6135	39786	D007654	39786
ketoconazole	venlafaxine	22	23	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  		6135	39786	D007654	39786
ketoconazole	venlafaxine	22	23	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  		6135	39786	D007654	39786
ketoconazole	venlafaxine	22	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		6135	39786	D007654	39786
ketoconazole	venlafaxine	22	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		6135	39786	D007654	39786
Indinavir	Venlafaxine	48	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
Indinavir	Venlafaxine	48	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
Indinavir	Venlafaxine	48	47	true	negative	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
Indinavir	Venlafaxine	48	47	true	negative	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
Indinavir	Venlafaxine	48	50	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of this finding is unknown.  CYP1A2    Venlafaxine did not inhibit CYP1A2 in vitro.  		none	39786	none	39786
Indinavir	Venlafaxine	48	50	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of this finding is unknown.  CYP1A2    Venlafaxine did not inhibit CYP1A2 in vitro.  		none	39786	none	39786
Indinavir	Venlafaxine	48	48	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
Indinavir	Venlafaxine	48	48	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
Indinavir	Venlafaxine	47	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		none	39786	none	39786
Indinavir	Venlafaxine	47	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		none	39786	none	39786
Indinavir	Venlafaxine	47	47	false	none	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		none	39786	none	39786
Indinavir	Venlafaxine	47	47	false	none	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		none	39786	none	39786
Indinavir	Venlafaxine	47	45	true	negative	CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		none	39786	none	39786
Indinavir	Venlafaxine	47	45	true	negative	CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		none	39786	none	39786
Indinavir	Venlafaxine	47	48	true	negative	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
Indinavir	Venlafaxine	47	48	true	negative	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
Indinavir	terfenadine	48	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	none	none	none
Indinavir	terfenadine	47	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		none	none	none	none
Indinavir	indinavir	48	48	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	none	none	none
Indinavir	indinavir	48	47	true	negative	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	none	none	none
Indinavir	indinavir	47	48	true	negative	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	none	none	none
Indinavir	indinavir	47	47	false	none	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		none	none	none	none
Indinavir	venlafaxine	48	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
Indinavir	venlafaxine	48	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
Indinavir	venlafaxine	48	47	true	negative	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
Indinavir	venlafaxine	48	47	true	negative	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
Indinavir	venlafaxine	48	50	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of this finding is unknown.  CYP1A2    Venlafaxine did not inhibit CYP1A2 in vitro.  		none	39786	none	39786
Indinavir	venlafaxine	48	50	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of this finding is unknown.  CYP1A2    Venlafaxine did not inhibit CYP1A2 in vitro.  		none	39786	none	39786
Indinavir	venlafaxine	48	48	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
Indinavir	venlafaxine	48	48	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
Indinavir	venlafaxine	47	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		none	39786	none	39786
Indinavir	venlafaxine	47	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		none	39786	none	39786
Indinavir	venlafaxine	47	47	false	none	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		none	39786	none	39786
Indinavir	venlafaxine	47	47	false	none	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		none	39786	none	39786
Indinavir	venlafaxine	47	45	true	negative	CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		none	39786	none	39786
Indinavir	venlafaxine	47	45	true	negative	CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		none	39786	none	39786
Indinavir	venlafaxine	47	48	true	negative	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
Indinavir	venlafaxine	47	48	true	negative	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
Venlafaxine	maoi	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	maoi	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	maoi	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	maoi	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	maoi	57	58	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	maoi	57	58	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	maoi	56	58	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	maoi	56	58	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	maoi	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	maoi	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	venlafaxine hydrochloride	17	17	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	16	17	false	none	Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	19	17	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	18	17	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	42	42	false	none	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	43	42	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	40	42	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	41	42	false	none	Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	44	42	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	59	59	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	59	60	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	58	59	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	57	59	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	57	58	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	56	58	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	62	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	62	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	60	59	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	60	62	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	60	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	68	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	68	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	69	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	69	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	70	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	67	68	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		39786	C047426
Venlafaxine	venlafaxine hydrochloride	67	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		39786	C047426
Venlafaxine	aspirin	62	63	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		39786	none	39786	none
Venlafaxine	aspirin	62	63	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		39786	none	39786	none
Venlafaxine	aspirin	67	65	false	none	These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		39786	none	39786	none
Venlafaxine	aspirin	67	65	false	none	These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		39786	none	39786	none
Venlafaxine	risperidone	42	43	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		39786	none	39786	none
Venlafaxine	risperidone	42	43	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		39786	none	39786	none
Venlafaxine	risperidone	42	44	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	none	39786	none
Venlafaxine	risperidone	42	44	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	none	39786	none
Venlafaxine	risperidone	43	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		39786	none	39786	none
Venlafaxine	risperidone	43	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		39786	none	39786	none
Venlafaxine	risperidone	43	44	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	none	39786	none
Venlafaxine	risperidone	43	44	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	none	39786	none
Venlafaxine	risperidone	41	43	true	positive	Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		39786	none	39786	none
Venlafaxine	risperidone	41	43	true	positive	Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		39786	none	39786	none
Venlafaxine	risperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		39786	none	39786	none
Venlafaxine	risperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		39786	none	39786	none
Venlafaxine	risperidone	44	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	none	39786	none
Venlafaxine	risperidone	44	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	none	39786	none
Venlafaxine	risperidone	44	44	false	none	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	none	39786	none
Venlafaxine	risperidone	44	44	false	none	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	none	39786	none
Venlafaxine	risperidone	45	43	true	negative	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  		39786	none	39786	none
Venlafaxine	risperidone	45	43	true	negative	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  		39786	none	39786	none
Venlafaxine	risperidone	45	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  		39786	none	39786	none
Venlafaxine	risperidone	45	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  		39786	none	39786	none
Venlafaxine	fluoxetine	29	30	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		39786	4493	39786	D005473
Venlafaxine	fluoxetine	29	30	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		39786	4493	39786	D005473
Venlafaxine	fluoxetine	28	30	false	none	Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		39786	4493	39786	D005473
Venlafaxine	fluoxetine	28	30	false	none	Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		39786	4493	39786	D005473
Venlafaxine	fluoxetine	31	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		39786	4493	39786	D005473
Venlafaxine	fluoxetine	31	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		39786	4493	39786	D005473
Venlafaxine	fluoxetine	30	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		39786	4493	39786	D005473
Venlafaxine	fluoxetine	30	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		39786	4493	39786	D005473
Venlafaxine	fluoxetine	32	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		39786	4493	39786	D005473
Venlafaxine	fluoxetine	32	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		39786	4493	39786	D005473
Venlafaxine	terfenadine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		39786	none	39786	none
Venlafaxine	terfenadine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		39786	none	39786	none
Venlafaxine	terfenadine	47	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		39786	none	39786	none
Venlafaxine	terfenadine	47	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		39786	none	39786	none
Venlafaxine	terfenadine	44	46	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		39786	none	39786	none
Venlafaxine	terfenadine	44	46	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		39786	none	39786	none
Venlafaxine	terfenadine	45	46	true	negative	CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		39786	none	39786	none
Venlafaxine	terfenadine	45	46	true	negative	CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		39786	none	39786	none
Venlafaxine	terfenadine	48	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		39786	none	39786	none
Venlafaxine	terfenadine	48	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		39786	none	39786	none
Venlafaxine	tolbutamide	51	53	false	none	This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  		39786	none	39786	none
Venlafaxine	tolbutamide	51	53	false	none	This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  		39786	none	39786	none
Venlafaxine	tolbutamide	54	53	false	none	In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		39786	none	39786	none
Venlafaxine	tolbutamide	54	53	false	none	In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		39786	none	39786	none
Venlafaxine	tolbutamide	53	53	false	none	In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  		39786	none	39786	none
Venlafaxine	tolbutamide	53	53	false	none	In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  		39786	none	39786	none
Venlafaxine	tolbutamide	52	53	false	none	CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  		39786	none	39786	none
Venlafaxine	tolbutamide	52	53	false	none	CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  		39786	none	39786	none
Venlafaxine	serotonin	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	serotonin	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	serotonin	59	61	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		39786	none	39786	none
Venlafaxine	serotonin	59	61	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		39786	none	39786	none
Venlafaxine	serotonin	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	serotonin	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	serotonin	57	58	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	serotonin	57	58	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	serotonin	56	58	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	serotonin	56	58	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	serotonin	62	64	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  		39786	none	39786	none
Venlafaxine	serotonin	62	64	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  		39786	none	39786	none
Venlafaxine	serotonin	62	63	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		39786	none	39786	none
Venlafaxine	serotonin	62	63	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		39786	none	39786	none
Venlafaxine	serotonin	62	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	serotonin	62	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	serotonin	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	serotonin	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	serotonin	60	61	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		39786	none	39786	none
Venlafaxine	serotonin	60	61	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		39786	none	39786	none
Venlafaxine	desmethyldiazepam	9	10	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		39786	3155	39786	D003708
Venlafaxine	desmethyldiazepam	9	10	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		39786	3155	39786	D003708
Venlafaxine	desmethyldiazepam	10	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		39786	3155	39786	D003708
Venlafaxine	desmethyldiazepam	10	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		39786	3155	39786	D003708
Venlafaxine	desmethyldiazepam	11	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		39786	3155	39786	D003708
Venlafaxine	desmethyldiazepam	11	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		39786	3155	39786	D003708
Venlafaxine	desmethyldiazepam	12	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		39786	3155	39786	D003708
Venlafaxine	desmethyldiazepam	12	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		39786	3155	39786	D003708
Venlafaxine	desipramine	31	32	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		39786	3247	39786	3247
Venlafaxine	desipramine	31	32	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		39786	3247	39786	3247
Venlafaxine	desipramine	31	33	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		39786	3247	39786	3247
Venlafaxine	desipramine	31	33	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		39786	3247	39786	3247
Venlafaxine	desipramine	30	32	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		39786	3247	39786	3247
Venlafaxine	desipramine	30	32	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		39786	3247	39786	3247
Venlafaxine	desipramine	34	35	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  		39786	3247	39786	3247
Venlafaxine	desipramine	34	35	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  		39786	3247	39786	3247
Venlafaxine	desipramine	34	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		39786	3247	39786	3247
Venlafaxine	desipramine	34	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		39786	3247	39786	3247
Venlafaxine	desipramine	34	33	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		39786	3247	39786	3247
Venlafaxine	desipramine	34	33	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		39786	3247	39786	3247
Venlafaxine	desipramine	32	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		39786	3247	39786	3247
Venlafaxine	desipramine	32	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		39786	3247	39786	3247
Venlafaxine	desipramine	32	33	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		39786	3247	39786	3247
Venlafaxine	desipramine	32	33	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		39786	3247	39786	3247
Venlafaxine	desipramine	33	35	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  		39786	3247	39786	3247
Venlafaxine	desipramine	33	35	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  		39786	3247	39786	3247
Venlafaxine	desipramine	33	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		39786	3247	39786	3247
Venlafaxine	desipramine	33	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		39786	3247	39786	3247
Venlafaxine	desipramine	33	33	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		39786	3247	39786	3247
Venlafaxine	desipramine	33	33	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		39786	3247	39786	3247
Venlafaxine	desipramine	36	35	true	negative	The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		39786	3247	39786	3247
Venlafaxine	desipramine	36	35	true	negative	The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		39786	3247	39786	3247
Venlafaxine	desipramine	37	35	true	negative	The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		39786	3247	39786	3247
Venlafaxine	desipramine	37	35	true	negative	The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		39786	3247	39786	3247
Venlafaxine	linezolid	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	linezolid	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	linezolid	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	linezolid	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	linezolid	57	58	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	linezolid	57	58	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	linezolid	56	58	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	linezolid	56	58	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	linezolid	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	linezolid	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	tramadol	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	tramadol	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	tramadol	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	tramadol	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	tramadol	57	58	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	tramadol	57	58	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	tramadol	56	58	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	tramadol	56	58	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	tramadol	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	tramadol	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	ethanol	1	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  		39786	448	39786	D000431
Venlafaxine	ethanol	1	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  		39786	448	39786	D000431
Venlafaxine	ethanol	1	2	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  		39786	448	39786	D000431
Venlafaxine	ethanol	1	2	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  		39786	448	39786	D000431
Venlafaxine	ethanol	2	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  		39786	448	39786	D000431
Venlafaxine	ethanol	2	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  		39786	448	39786	D000431
Venlafaxine	ethanol	2	2	false	none	Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  		39786	448	39786	D000431
Venlafaxine	ethanol	2	2	false	none	Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  		39786	448	39786	D000431
Venlafaxine	ethanol	3	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		39786	448	39786	D000431
Venlafaxine	ethanol	3	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		39786	448	39786	D000431
Venlafaxine	ethanol	3	2	false	none	Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		39786	448	39786	D000431
Venlafaxine	ethanol	3	2	false	none	Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		39786	448	39786	D000431
Venlafaxine	ethanol	4	2	false	none	Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  		39786	448	39786	D000431
Venlafaxine	ethanol	4	2	false	none	Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  		39786	448	39786	D000431
Venlafaxine	indinavir	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		39786	none	39786	none
Venlafaxine	indinavir	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		39786	none	39786	none
Venlafaxine	indinavir	46	47	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		39786	none	39786	none
Venlafaxine	indinavir	46	47	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		39786	none	39786	none
Venlafaxine	indinavir	47	48	true	negative	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		39786	none	39786	none
Venlafaxine	indinavir	47	48	true	negative	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		39786	none	39786	none
Venlafaxine	indinavir	47	47	false	none	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		39786	none	39786	none
Venlafaxine	indinavir	47	47	false	none	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		39786	none	39786	none
Venlafaxine	indinavir	45	47	true	negative	CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		39786	none	39786	none
Venlafaxine	indinavir	45	47	true	negative	CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		39786	none	39786	none
Venlafaxine	indinavir	50	48	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of this finding is unknown.  CYP1A2    Venlafaxine did not inhibit CYP1A2 in vitro.  		39786	none	39786	none
Venlafaxine	indinavir	50	48	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of this finding is unknown.  CYP1A2    Venlafaxine did not inhibit CYP1A2 in vitro.  		39786	none	39786	none
Venlafaxine	indinavir	48	48	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		39786	none	39786	none
Venlafaxine	indinavir	48	48	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		39786	none	39786	none
Venlafaxine	indinavir	48	47	true	negative	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		39786	none	39786	none
Venlafaxine	indinavir	48	47	true	negative	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		39786	none	39786	none
Venlafaxine	venlafaxine	1	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  		39786	39786
Venlafaxine	venlafaxine	1	2	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  		39786	39786
Venlafaxine	venlafaxine	1	3	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		39786	39786
Venlafaxine	venlafaxine	2	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  		39786	39786
Venlafaxine	venlafaxine	2	2	false	none	Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  		39786	39786
Venlafaxine	venlafaxine	2	3	false	none	Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		39786	39786
Venlafaxine	venlafaxine	2	4	false	none	Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  		39786	39786
Venlafaxine	venlafaxine	3	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		39786	39786
Venlafaxine	venlafaxine	3	2	false	none	Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		39786	39786
Venlafaxine	venlafaxine	3	3	true	positive	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		39786	39786
Venlafaxine	venlafaxine	3	4	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  		39786	39786
Venlafaxine	venlafaxine	3	5	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		39786	39786
Venlafaxine	venlafaxine	4	2	false	none	Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  		39786	39786
Venlafaxine	venlafaxine	4	3	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  		39786	39786
Venlafaxine	venlafaxine	4	4	false	none	The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  		39786	39786
Venlafaxine	venlafaxine	4	5	false	none	The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		39786	39786
Venlafaxine	venlafaxine	4	6	false	none	The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		39786	39786
Venlafaxine	venlafaxine	5	3	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		39786	39786
Venlafaxine	venlafaxine	5	4	false	none	The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		39786	39786
Venlafaxine	venlafaxine	5	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		39786	39786
Venlafaxine	venlafaxine	5	6	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		39786	39786
Venlafaxine	venlafaxine	5	7	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		39786	39786
Venlafaxine	venlafaxine	6	4	false	none	The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		39786	39786
Venlafaxine	venlafaxine	6	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		39786	39786
Venlafaxine	venlafaxine	6	6	false	none	The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		39786	39786
Venlafaxine	venlafaxine	6	7	false	none	The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		39786	39786
Venlafaxine	venlafaxine	7	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		39786	39786
Venlafaxine	venlafaxine	7	6	false	none	The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		39786	39786
Venlafaxine	venlafaxine	7	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		39786	39786
Venlafaxine	venlafaxine	7	9	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		39786	39786
Venlafaxine	venlafaxine	9	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		39786	39786
Venlafaxine	venlafaxine	9	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		39786	39786
Venlafaxine	venlafaxine	9	10	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		39786	39786
Venlafaxine	venlafaxine	9	11	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		39786	39786
Venlafaxine	venlafaxine	10	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		39786	39786
Venlafaxine	venlafaxine	10	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		39786	39786
Venlafaxine	venlafaxine	10	11	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		39786	39786
Venlafaxine	venlafaxine	10	12	true	negative	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		39786	39786
Venlafaxine	venlafaxine	11	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		39786	39786
Venlafaxine	venlafaxine	11	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		39786	39786
Venlafaxine	venlafaxine	11	11	true	positive	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		39786	39786
Venlafaxine	venlafaxine	11	12	true	positive	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		39786	39786
Venlafaxine	venlafaxine	12	10	true	negative	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		39786	39786
Venlafaxine	venlafaxine	12	11	true	positive	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		39786	39786
Venlafaxine	venlafaxine	12	12	true	positive	In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		39786	39786
Venlafaxine	venlafaxine	12	14	true	negative	In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  The mechanism explaining this finding is unknown.  7.5 Lithium    The steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects.  		39786	39786
Venlafaxine	venlafaxine	14	12	true	negative	In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  The mechanism explaining this finding is unknown.  7.5 Lithium    The steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects.  		39786	39786
Venlafaxine	venlafaxine	14	14	true	negative	7.5 Lithium    The steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects.  		39786	39786
Venlafaxine	venlafaxine	14	16	true	negative	7.5 Lithium    The steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects.  ODV also was unaffected.  Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  		39786	39786
Venlafaxine	venlafaxine	17	17	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  		39786	39786
Venlafaxine	venlafaxine	17	16	false	none	Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  		39786	39786
Venlafaxine	venlafaxine	17	19	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		39786	39786
Venlafaxine	venlafaxine	17	18	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		39786	39786
Venlafaxine	venlafaxine	16	14	true	negative	7.5 Lithium    The steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects.  ODV also was unaffected.  Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  		39786	39786
Venlafaxine	venlafaxine	16	17	false	none	Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  		39786	39786
Venlafaxine	venlafaxine	16	16	false	none	Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  		39786	39786
Venlafaxine	venlafaxine	16	18	false	none	Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		39786	39786
Venlafaxine	venlafaxine	19	17	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		39786	39786
Venlafaxine	venlafaxine	19	19	false	none	Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		39786	39786
Venlafaxine	venlafaxine	19	18	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		39786	39786
Venlafaxine	venlafaxine	19	21	false	none	Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  		39786	39786
Venlafaxine	venlafaxine	18	17	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		39786	39786
Venlafaxine	venlafaxine	18	16	false	none	Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		39786	39786
Venlafaxine	venlafaxine	18	19	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		39786	39786
Venlafaxine	venlafaxine	18	18	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		39786	39786
Venlafaxine	venlafaxine	21	19	false	none	Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)].  Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  		39786	39786
Venlafaxine	venlafaxine	21	21	false	none	Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  		39786	39786
Venlafaxine	venlafaxine	21	23	true	positive	Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  		39786	39786
Venlafaxine	venlafaxine	21	22	false	none	Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		39786	39786
Venlafaxine	venlafaxine	23	21	true	positive	Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  		39786	39786
Venlafaxine	venlafaxine	23	23	true	positive	Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  		39786	39786
Venlafaxine	venlafaxine	23	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  		39786	39786
Venlafaxine	venlafaxine	23	25	true	positive	Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.  Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  		39786	39786
Venlafaxine	venlafaxine	22	21	false	none	Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.  Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		39786	39786
Venlafaxine	venlafaxine	22	23	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  		39786	39786
Venlafaxine	venlafaxine	22	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.  		39786	39786
Venlafaxine	venlafaxine	25	23	true	positive	Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects.  Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.  Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  		39786	39786
Venlafaxine	venlafaxine	25	25	true	positive	Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  		39786	39786
Venlafaxine	venlafaxine	25	27	true	positive	Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  		39786	39786
Venlafaxine	venlafaxine	25	26	true	positive	Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  		39786	39786
Venlafaxine	venlafaxine	27	25	true	positive	Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  		39786	39786
Venlafaxine	venlafaxine	27	27	false	none	Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  		39786	39786
Venlafaxine	venlafaxine	27	26	true	positive	Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  		39786	39786
Venlafaxine	venlafaxine	27	29	false	none	Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  		39786	39786
Venlafaxine	venlafaxine	27	28	false	none	Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  		39786	39786
Venlafaxine	venlafaxine	26	25	true	positive	Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively.  Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  		39786	39786
Venlafaxine	venlafaxine	26	27	true	positive	Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  		39786	39786
Venlafaxine	venlafaxine	26	26	true	positive	Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  		39786	39786
Venlafaxine	venlafaxine	26	28	true	positive	Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  		39786	39786
Venlafaxine	venlafaxine	29	27	false	none	Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  		39786	39786
Venlafaxine	venlafaxine	29	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  		39786	39786
Venlafaxine	venlafaxine	29	28	false	none	Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  		39786	39786
Venlafaxine	venlafaxine	29	31	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		39786	39786
Venlafaxine	venlafaxine	29	30	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		39786	39786
Venlafaxine	venlafaxine	28	27	false	none	Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  		39786	39786
Venlafaxine	venlafaxine	28	26	true	positive	Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).  Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  		39786	39786
Venlafaxine	venlafaxine	28	29	false	none	Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  		39786	39786
Venlafaxine	venlafaxine	28	28	false	none	Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  		39786	39786
Venlafaxine	venlafaxine	28	30	false	none	Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		39786	39786
Venlafaxine	venlafaxine	31	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		39786	39786
Venlafaxine	venlafaxine	31	31	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		39786	39786
Venlafaxine	venlafaxine	31	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		39786	39786
Venlafaxine	venlafaxine	31	32	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		39786	39786
Venlafaxine	venlafaxine	31	33	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		39786	39786
Venlafaxine	venlafaxine	30	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		39786	39786
Venlafaxine	venlafaxine	30	28	false	none	Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		39786	39786
Venlafaxine	venlafaxine	30	31	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		39786	39786
Venlafaxine	venlafaxine	30	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		39786	39786
Venlafaxine	venlafaxine	30	32	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		39786	39786
Venlafaxine	venlafaxine	34	34	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		39786	39786
Venlafaxine	venlafaxine	34	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		39786	39786
Venlafaxine	venlafaxine	34	33	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		39786	39786
Venlafaxine	venlafaxine	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		39786	39786
Venlafaxine	venlafaxine	32	31	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		39786	39786
Venlafaxine	venlafaxine	32	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		39786	39786
Venlafaxine	venlafaxine	32	34	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		39786	39786
Venlafaxine	venlafaxine	32	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		39786	39786
Venlafaxine	venlafaxine	32	33	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		39786	39786
Venlafaxine	venlafaxine	33	31	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		39786	39786
Venlafaxine	venlafaxine	33	34	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		39786	39786
Venlafaxine	venlafaxine	33	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		39786	39786
Venlafaxine	venlafaxine	33	33	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		39786	39786
Venlafaxine	venlafaxine	38	38	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	39786
Venlafaxine	venlafaxine	38	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	39786
Venlafaxine	venlafaxine	38	37	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	39786
Venlafaxine	venlafaxine	38	40	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  The clinical relevance of this finding for hypertensive patients is unknown.  Caution should be exercised with co-administration of venlafaxine and metoprolol.  		39786	39786
Venlafaxine	venlafaxine	36	34	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		39786	39786
Venlafaxine	venlafaxine	36	38	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	39786
Venlafaxine	venlafaxine	36	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		39786	39786
Venlafaxine	venlafaxine	36	37	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		39786	39786
Venlafaxine	venlafaxine	37	38	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	39786
Venlafaxine	venlafaxine	37	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		39786	39786
Venlafaxine	venlafaxine	37	37	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		39786	39786
Venlafaxine	venlafaxine	42	42	false	none	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		39786	39786
Venlafaxine	venlafaxine	42	43	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		39786	39786
Venlafaxine	venlafaxine	42	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		39786	39786
Venlafaxine	venlafaxine	42	41	false	none	Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		39786	39786
Venlafaxine	venlafaxine	42	44	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	39786
Venlafaxine	venlafaxine	43	42	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		39786	39786
Venlafaxine	venlafaxine	43	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		39786	39786
Venlafaxine	venlafaxine	43	41	true	positive	Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		39786	39786
Venlafaxine	venlafaxine	43	44	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	39786
Venlafaxine	venlafaxine	43	45	true	negative	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  		39786	39786
Venlafaxine	venlafaxine	40	38	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  The clinical relevance of this finding for hypertensive patients is unknown.  Caution should be exercised with co-administration of venlafaxine and metoprolol.  		39786	39786
Venlafaxine	venlafaxine	40	42	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		39786	39786
Venlafaxine	venlafaxine	40	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  		39786	39786
Venlafaxine	venlafaxine	40	41	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  		39786	39786
Venlafaxine	venlafaxine	41	42	false	none	Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		39786	39786
Venlafaxine	venlafaxine	41	43	true	positive	Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		39786	39786
Venlafaxine	venlafaxine	41	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  		39786	39786
Venlafaxine	venlafaxine	41	41	true	positive	Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  		39786	39786
Venlafaxine	venlafaxine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		39786	39786
Venlafaxine	venlafaxine	46	47	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		39786	39786
Venlafaxine	venlafaxine	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		39786	39786
Venlafaxine	venlafaxine	46	45	true	negative	CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		39786	39786
Venlafaxine	venlafaxine	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		39786	39786
Venlafaxine	venlafaxine	47	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		39786	39786
Venlafaxine	venlafaxine	47	47	false	none	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		39786	39786
Venlafaxine	venlafaxine	47	45	true	negative	CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		39786	39786
Venlafaxine	venlafaxine	47	48	true	negative	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		39786	39786
Venlafaxine	venlafaxine	44	42	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	39786
Venlafaxine	venlafaxine	44	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	39786
Venlafaxine	venlafaxine	44	46	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		39786	39786
Venlafaxine	venlafaxine	44	44	false	none	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	39786
Venlafaxine	venlafaxine	44	45	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  		39786	39786
Venlafaxine	venlafaxine	45	43	true	negative	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  		39786	39786
Venlafaxine	venlafaxine	45	46	true	negative	CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		39786	39786
Venlafaxine	venlafaxine	45	47	true	negative	CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		39786	39786
Venlafaxine	venlafaxine	45	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  		39786	39786
Venlafaxine	venlafaxine	45	45	true	negative	CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  		39786	39786
Venlafaxine	venlafaxine	51	51	true	negative	This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  		39786	39786
Venlafaxine	venlafaxine	51	50	true	negative	CYP1A2    Venlafaxine did not inhibit CYP1A2 in vitro.  This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  		39786	39786
Venlafaxine	venlafaxine	51	53	false	none	This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  		39786	39786
Venlafaxine	venlafaxine	51	52	true	negative	This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  		39786	39786
Venlafaxine	venlafaxine	50	51	true	negative	CYP1A2    Venlafaxine did not inhibit CYP1A2 in vitro.  This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  		39786	39786
Venlafaxine	venlafaxine	50	50	true	negative	CYP1A2    Venlafaxine did not inhibit CYP1A2 in vitro.  		39786	39786
Venlafaxine	venlafaxine	50	48	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of this finding is unknown.  CYP1A2    Venlafaxine did not inhibit CYP1A2 in vitro.  		39786	39786
Venlafaxine	venlafaxine	50	52	true	negative	CYP1A2    Venlafaxine did not inhibit CYP1A2 in vitro.  This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  		39786	39786
Venlafaxine	venlafaxine	48	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		39786	39786
Venlafaxine	venlafaxine	48	47	true	negative	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		39786	39786
Venlafaxine	venlafaxine	48	50	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of this finding is unknown.  CYP1A2    Venlafaxine did not inhibit CYP1A2 in vitro.  		39786	39786
Venlafaxine	venlafaxine	48	48	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		39786	39786
Venlafaxine	venlafaxine	54	54	true	negative	CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		39786	39786
Venlafaxine	venlafaxine	54	53	false	none	In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		39786	39786
Venlafaxine	venlafaxine	54	52	false	none	CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		39786	39786
Venlafaxine	venlafaxine	54	56	false	none	CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  7.9 Monoamine Oxidase Inhibitors    See Contraindications (4) and Warnings and Precautions (5.2).  7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  		39786	39786
Venlafaxine	venlafaxine	53	51	false	none	This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  		39786	39786
Venlafaxine	venlafaxine	53	54	false	none	In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		39786	39786
Venlafaxine	venlafaxine	53	53	false	none	In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  		39786	39786
Venlafaxine	venlafaxine	53	52	false	none	CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  		39786	39786
Venlafaxine	venlafaxine	52	51	true	negative	This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  		39786	39786
Venlafaxine	venlafaxine	52	50	true	negative	CYP1A2    Venlafaxine did not inhibit CYP1A2 in vitro.  This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  		39786	39786
Venlafaxine	venlafaxine	52	54	false	none	CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		39786	39786
Venlafaxine	venlafaxine	52	53	false	none	CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  		39786	39786
Venlafaxine	venlafaxine	52	52	true	negative	CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  		39786	39786
Venlafaxine	venlafaxine	59	59	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	39786
Venlafaxine	venlafaxine	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	39786
Venlafaxine	venlafaxine	59	57	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	39786
Venlafaxine	venlafaxine	59	60	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	39786
Venlafaxine	venlafaxine	58	59	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	39786
Venlafaxine	venlafaxine	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	39786
Venlafaxine	venlafaxine	58	57	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	39786
Venlafaxine	venlafaxine	58	56	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	39786
Venlafaxine	venlafaxine	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	39786
Venlafaxine	venlafaxine	57	59	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	39786
Venlafaxine	venlafaxine	57	58	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	39786
Venlafaxine	venlafaxine	57	57	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  		39786	39786
Venlafaxine	venlafaxine	57	56	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  		39786	39786
Venlafaxine	venlafaxine	56	54	false	none	CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  7.9 Monoamine Oxidase Inhibitors    See Contraindications (4) and Warnings and Precautions (5.2).  7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  		39786	39786
Venlafaxine	venlafaxine	56	58	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	39786
Venlafaxine	venlafaxine	56	57	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  		39786	39786
Venlafaxine	venlafaxine	56	56	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  		39786	39786
Venlafaxine	venlafaxine	62	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	39786
Venlafaxine	venlafaxine	62	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	39786
Venlafaxine	venlafaxine	60	59	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	39786
Venlafaxine	venlafaxine	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	39786
Venlafaxine	venlafaxine	60	62	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	39786
Venlafaxine	venlafaxine	60	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	39786
Venlafaxine	venlafaxine	68	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		39786	39786
Venlafaxine	venlafaxine	68	69	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		39786	39786
Venlafaxine	venlafaxine	68	70	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		39786	39786
Venlafaxine	venlafaxine	68	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		39786	39786
Venlafaxine	venlafaxine	69	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		39786	39786
Venlafaxine	venlafaxine	69	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		39786	39786
Venlafaxine	venlafaxine	69	70	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		39786	39786
Venlafaxine	venlafaxine	69	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		39786	39786
Venlafaxine	venlafaxine	70	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		39786	39786
Venlafaxine	venlafaxine	70	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		39786	39786
Venlafaxine	venlafaxine	70	70	false	none	There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		39786	39786
Venlafaxine	venlafaxine	67	68	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		39786	39786
Venlafaxine	venlafaxine	67	69	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		39786	39786
Venlafaxine	venlafaxine	67	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		39786	39786
Venlafaxine	tryptophan	59	60	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	tryptophan	59	60	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	tryptophan	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	tryptophan	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	tryptophan	62	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	tryptophan	62	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	tryptophan	60	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	tryptophan	60	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	Metoprolol	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		39786	6918	39786	D008790
Venlafaxine	Metoprolol	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		39786	6918	39786	D008790
Venlafaxine	Metoprolol	38	38	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
Venlafaxine	Metoprolol	38	38	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
Venlafaxine	Metoprolol	38	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
Venlafaxine	Metoprolol	38	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
Venlafaxine	Metoprolol	38	37	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
Venlafaxine	Metoprolol	38	37	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
Venlafaxine	Metoprolol	38	40	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  The clinical relevance of this finding for hypertensive patients is unknown.  Caution should be exercised with co-administration of venlafaxine and metoprolol.  		39786	6918	39786	D008790
Venlafaxine	Metoprolol	38	40	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  The clinical relevance of this finding for hypertensive patients is unknown.  Caution should be exercised with co-administration of venlafaxine and metoprolol.  		39786	6918	39786	D008790
Venlafaxine	Metoprolol	36	38	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
Venlafaxine	Metoprolol	36	38	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
Venlafaxine	Metoprolol	36	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		39786	6918	39786	D008790
Venlafaxine	Metoprolol	36	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		39786	6918	39786	D008790
Venlafaxine	Metoprolol	36	37	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		39786	6918	39786	D008790
Venlafaxine	Metoprolol	36	37	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		39786	6918	39786	D008790
Venlafaxine	Metoprolol	37	38	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
Venlafaxine	Metoprolol	37	38	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
Venlafaxine	Metoprolol	37	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		39786	6918	39786	D008790
Venlafaxine	Metoprolol	37	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		39786	6918	39786	D008790
Venlafaxine	Metoprolol	37	37	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		39786	6918	39786	D008790
Venlafaxine	Metoprolol	37	37	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		39786	6918	39786	D008790
Venlafaxine	Metoprolol	42	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		39786	6918	39786	D008790
Venlafaxine	Metoprolol	42	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		39786	6918	39786	D008790
Venlafaxine	Metoprolol	40	38	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  The clinical relevance of this finding for hypertensive patients is unknown.  Caution should be exercised with co-administration of venlafaxine and metoprolol.  		39786	6918	39786	D008790
Venlafaxine	Metoprolol	40	38	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  The clinical relevance of this finding for hypertensive patients is unknown.  Caution should be exercised with co-administration of venlafaxine and metoprolol.  		39786	6918	39786	D008790
Venlafaxine	Metoprolol	40	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  		39786	6918	39786	D008790
Venlafaxine	Metoprolol	40	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  		39786	6918	39786	D008790
Venlafaxine	Metoprolol	41	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  		39786	6918	39786	D008790
Venlafaxine	Metoprolol	41	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  		39786	6918	39786	D008790
Venlafaxine	Haloperidol	9	11	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		39786	5093	39786	D006220
Venlafaxine	Haloperidol	9	11	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		39786	5093	39786	D006220
Venlafaxine	Haloperidol	10	11	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		39786	5093	39786	D006220
Venlafaxine	Haloperidol	10	11	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		39786	5093	39786	D006220
Venlafaxine	Haloperidol	10	12	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		39786	5093	39786	D006220
Venlafaxine	Haloperidol	10	12	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		39786	5093	39786	D006220
Venlafaxine	Haloperidol	11	11	true	positive	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		39786	5093	39786	D006220
Venlafaxine	Haloperidol	11	11	true	positive	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		39786	5093	39786	D006220
Venlafaxine	Haloperidol	11	12	false	none	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		39786	5093	39786	D006220
Venlafaxine	Haloperidol	11	12	false	none	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		39786	5093	39786	D006220
Venlafaxine	Haloperidol	12	11	false	none	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		39786	5093	39786	D006220
Venlafaxine	Haloperidol	12	11	false	none	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		39786	5093	39786	D006220
Venlafaxine	Haloperidol	12	12	false	none	In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		39786	5093	39786	D006220
Venlafaxine	Haloperidol	12	12	false	none	In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		39786	5093	39786	D006220
Venlafaxine	Haloperidol	14	12	true	negative	In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  The mechanism explaining this finding is unknown.  7.5 Lithium    The steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects.  		39786	5093	39786	D006220
Venlafaxine	Haloperidol	14	12	true	negative	In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  The mechanism explaining this finding is unknown.  7.5 Lithium    The steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects.  		39786	5093	39786	D006220
Venlafaxine	9-hydroxyrisperidone	42	43	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		39786	none	39786	none
Venlafaxine	9-hydroxyrisperidone	42	43	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		39786	none	39786	none
Venlafaxine	9-hydroxyrisperidone	42	44	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	none	39786	none
Venlafaxine	9-hydroxyrisperidone	42	44	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	none	39786	none
Venlafaxine	9-hydroxyrisperidone	43	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		39786	none	39786	none
Venlafaxine	9-hydroxyrisperidone	43	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		39786	none	39786	none
Venlafaxine	9-hydroxyrisperidone	43	44	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	none	39786	none
Venlafaxine	9-hydroxyrisperidone	43	44	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	none	39786	none
Venlafaxine	9-hydroxyrisperidone	41	43	true	positive	Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		39786	none	39786	none
Venlafaxine	9-hydroxyrisperidone	41	43	true	positive	Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		39786	none	39786	none
Venlafaxine	9-hydroxyrisperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		39786	none	39786	none
Venlafaxine	9-hydroxyrisperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		39786	none	39786	none
Venlafaxine	9-hydroxyrisperidone	44	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	none	39786	none
Venlafaxine	9-hydroxyrisperidone	44	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	none	39786	none
Venlafaxine	9-hydroxyrisperidone	44	44	false	none	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	none	39786	none
Venlafaxine	9-hydroxyrisperidone	44	44	false	none	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	none	39786	none
Venlafaxine	9-hydroxyrisperidone	45	43	true	negative	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  		39786	none	39786	none
Venlafaxine	9-hydroxyrisperidone	45	43	true	negative	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  		39786	none	39786	none
Venlafaxine	9-hydroxyrisperidone	45	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  		39786	none	39786	none
Venlafaxine	9-hydroxyrisperidone	45	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  		39786	none	39786	none
Venlafaxine	dextromethorphan	29	30	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		39786	0	39786	D003915
Venlafaxine	dextromethorphan	29	30	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		39786	0	39786	D003915
Venlafaxine	dextromethorphan	28	30	false	none	Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		39786	0	39786	D003915
Venlafaxine	dextromethorphan	28	30	false	none	Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		39786	0	39786	D003915
Venlafaxine	dextromethorphan	31	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		39786	0	39786	D003915
Venlafaxine	dextromethorphan	31	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		39786	0	39786	D003915
Venlafaxine	dextromethorphan	30	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		39786	0	39786	D003915
Venlafaxine	dextromethorphan	30	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		39786	0	39786	D003915
Venlafaxine	dextromethorphan	32	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		39786	0	39786	D003915
Venlafaxine	dextromethorphan	32	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		39786	0	39786	D003915
Venlafaxine	clozapine	68	69	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		39786	none	39786	none
Venlafaxine	clozapine	68	69	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		39786	none	39786	none
Venlafaxine	clozapine	69	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		39786	none	39786	none
Venlafaxine	clozapine	69	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		39786	none	39786	none
Venlafaxine	clozapine	70	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		39786	none	39786	none
Venlafaxine	clozapine	70	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		39786	none	39786	none
Venlafaxine	clozapine	67	69	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		39786	none	39786	none
Venlafaxine	clozapine	67	69	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		39786	none	39786	none
Venlafaxine	Cimetidine	1	3	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		39786	2541	39786	2541
Venlafaxine	Cimetidine	1	3	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		39786	2541	39786	2541
Venlafaxine	Cimetidine	2	3	false	none	Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		39786	2541	39786	2541
Venlafaxine	Cimetidine	2	3	false	none	Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		39786	2541	39786	2541
Venlafaxine	Cimetidine	3	3	true	positive	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		39786	2541	39786	2541
Venlafaxine	Cimetidine	3	3	true	positive	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		39786	2541	39786	2541
Venlafaxine	Cimetidine	3	5	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		39786	2541	39786	2541
Venlafaxine	Cimetidine	3	5	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		39786	2541	39786	2541
Venlafaxine	Cimetidine	4	3	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  		39786	2541	39786	2541
Venlafaxine	Cimetidine	4	3	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  		39786	2541	39786	2541
Venlafaxine	Cimetidine	4	5	false	none	The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		39786	2541	39786	2541
Venlafaxine	Cimetidine	4	5	false	none	The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		39786	2541	39786	2541
Venlafaxine	Cimetidine	5	3	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		39786	2541	39786	2541
Venlafaxine	Cimetidine	5	3	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		39786	2541	39786	2541
Venlafaxine	Cimetidine	5	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		39786	2541	39786	2541
Venlafaxine	Cimetidine	5	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		39786	2541	39786	2541
Venlafaxine	Cimetidine	5	7	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		39786	2541	39786	2541
Venlafaxine	Cimetidine	5	7	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		39786	2541	39786	2541
Venlafaxine	Cimetidine	6	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		39786	2541	39786	2541
Venlafaxine	Cimetidine	6	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		39786	2541	39786	2541
Venlafaxine	Cimetidine	6	7	false	none	The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		39786	2541	39786	2541
Venlafaxine	Cimetidine	6	7	false	none	The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		39786	2541	39786	2541
Venlafaxine	Cimetidine	7	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		39786	2541	39786	2541
Venlafaxine	Cimetidine	7	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		39786	2541	39786	2541
Venlafaxine	Cimetidine	7	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		39786	2541	39786	2541
Venlafaxine	Cimetidine	7	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		39786	2541	39786	2541
Venlafaxine	Cimetidine	9	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		39786	2541	39786	2541
Venlafaxine	Cimetidine	9	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		39786	2541	39786	2541
Venlafaxine	metoprolol	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		39786	6918	39786	D008790
Venlafaxine	metoprolol	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		39786	6918	39786	D008790
Venlafaxine	metoprolol	38	38	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
Venlafaxine	metoprolol	38	38	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
Venlafaxine	metoprolol	38	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
Venlafaxine	metoprolol	38	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
Venlafaxine	metoprolol	38	37	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
Venlafaxine	metoprolol	38	37	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
Venlafaxine	metoprolol	38	40	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  The clinical relevance of this finding for hypertensive patients is unknown.  Caution should be exercised with co-administration of venlafaxine and metoprolol.  		39786	6918	39786	D008790
Venlafaxine	metoprolol	38	40	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  The clinical relevance of this finding for hypertensive patients is unknown.  Caution should be exercised with co-administration of venlafaxine and metoprolol.  		39786	6918	39786	D008790
Venlafaxine	metoprolol	36	38	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
Venlafaxine	metoprolol	36	38	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
Venlafaxine	metoprolol	36	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		39786	6918	39786	D008790
Venlafaxine	metoprolol	36	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		39786	6918	39786	D008790
Venlafaxine	metoprolol	36	37	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		39786	6918	39786	D008790
Venlafaxine	metoprolol	36	37	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		39786	6918	39786	D008790
Venlafaxine	metoprolol	37	38	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
Venlafaxine	metoprolol	37	38	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
Venlafaxine	metoprolol	37	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		39786	6918	39786	D008790
Venlafaxine	metoprolol	37	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		39786	6918	39786	D008790
Venlafaxine	metoprolol	37	37	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		39786	6918	39786	D008790
Venlafaxine	metoprolol	37	37	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		39786	6918	39786	D008790
Venlafaxine	metoprolol	42	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		39786	6918	39786	D008790
Venlafaxine	metoprolol	42	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		39786	6918	39786	D008790
Venlafaxine	metoprolol	40	38	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  The clinical relevance of this finding for hypertensive patients is unknown.  Caution should be exercised with co-administration of venlafaxine and metoprolol.  		39786	6918	39786	D008790
Venlafaxine	metoprolol	40	38	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  The clinical relevance of this finding for hypertensive patients is unknown.  Caution should be exercised with co-administration of venlafaxine and metoprolol.  		39786	6918	39786	D008790
Venlafaxine	metoprolol	40	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  		39786	6918	39786	D008790
Venlafaxine	metoprolol	40	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  		39786	6918	39786	D008790
Venlafaxine	metoprolol	41	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  		39786	6918	39786	D008790
Venlafaxine	metoprolol	41	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  		39786	6918	39786	D008790
Venlafaxine	p450	17	18	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		39786	none	39786	none
Venlafaxine	p450	17	18	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		39786	none	39786	none
Venlafaxine	p450	16	18	false	none	Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		39786	none	39786	none
Venlafaxine	p450	16	18	false	none	Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		39786	none	39786	none
Venlafaxine	p450	19	18	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		39786	none	39786	none
Venlafaxine	p450	19	18	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		39786	none	39786	none
Venlafaxine	p450	18	18	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		39786	none	39786	none
Venlafaxine	p450	18	18	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		39786	none	39786	none
Venlafaxine	p450	27	29	false	none	Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  		39786	none	39786	none
Venlafaxine	p450	27	29	false	none	Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  		39786	none	39786	none
Venlafaxine	p450	29	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  		39786	none	39786	none
Venlafaxine	p450	29	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  		39786	none	39786	none
Venlafaxine	p450	28	29	false	none	Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  		39786	none	39786	none
Venlafaxine	p450	28	29	false	none	Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  		39786	none	39786	none
Venlafaxine	p450	31	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		39786	none	39786	none
Venlafaxine	p450	31	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		39786	none	39786	none
Venlafaxine	p450	30	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		39786	none	39786	none
Venlafaxine	p450	30	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		39786	none	39786	none
Venlafaxine	triptan	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	triptan	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	triptan	59	61	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		39786	none	39786	none
Venlafaxine	triptan	59	61	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		39786	none	39786	none
Venlafaxine	triptan	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	triptan	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	triptan	57	58	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	triptan	57	58	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	triptan	56	58	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	triptan	56	58	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	triptan	62	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	triptan	62	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	triptan	62	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	triptan	62	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	triptan	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	triptan	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	triptan	60	62	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	triptan	60	62	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
Venlafaxine	triptan	60	61	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		39786	none	39786	none
Venlafaxine	triptan	60	61	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		39786	none	39786	none
maoi	venlafaxine hydrochloride	58	59	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
maoi	venlafaxine hydrochloride	58	59	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
maoi	venlafaxine hydrochloride	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
maoi	venlafaxine hydrochloride	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
maoi	venlafaxine hydrochloride	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
maoi	venlafaxine hydrochloride	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	C047426
maoi	serotonin	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	none	none	none
maoi	linezolid	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	none	none	none
maoi	tramadol	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	none	none	none
maoi	venlafaxine	58	59	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
maoi	venlafaxine	58	59	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
maoi	venlafaxine	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
maoi	venlafaxine	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
maoi	venlafaxine	58	57	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
maoi	venlafaxine	58	57	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
maoi	venlafaxine	58	56	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
maoi	venlafaxine	58	56	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
maoi	venlafaxine	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
maoi	venlafaxine	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
maoi	tryptophan	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	none	none	none
maoi	triptan	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	none	none	none
venlafaxine hydrochloride	aspirin	67	65	false	none	These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		39786	none	C047426	none
venlafaxine hydrochloride	aspirin	67	65	false	none	These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		39786	none	C047426	none
venlafaxine hydrochloride	aspirin	62	63	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		39786	none	C047426	none
venlafaxine hydrochloride	aspirin	62	63	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		39786	none	C047426	none
venlafaxine hydrochloride	risperidone	42	43	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		39786	none	C047426	none
venlafaxine hydrochloride	risperidone	42	43	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		39786	none	C047426	none
venlafaxine hydrochloride	risperidone	42	44	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	none	C047426	none
venlafaxine hydrochloride	risperidone	42	44	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	none	C047426	none
venlafaxine hydrochloride	serotonin	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	serotonin	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	serotonin	59	61	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		39786	none	C047426	none
venlafaxine hydrochloride	serotonin	59	61	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		39786	none	C047426	none
venlafaxine hydrochloride	serotonin	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	serotonin	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	serotonin	62	64	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  		39786	none	C047426	none
venlafaxine hydrochloride	serotonin	62	64	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  		39786	none	C047426	none
venlafaxine hydrochloride	serotonin	62	63	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		39786	none	C047426	none
venlafaxine hydrochloride	serotonin	62	63	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		39786	none	C047426	none
venlafaxine hydrochloride	serotonin	62	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	serotonin	62	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	serotonin	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	serotonin	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	serotonin	60	61	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		39786	none	C047426	none
venlafaxine hydrochloride	serotonin	60	61	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		39786	none	C047426	none
venlafaxine hydrochloride	linezolid	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	linezolid	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	linezolid	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	linezolid	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	linezolid	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	linezolid	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	tramadol	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	tramadol	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	tramadol	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	tramadol	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	tramadol	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	tramadol	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	venlafaxine	68	68	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		C047426	39786
venlafaxine hydrochloride	venlafaxine	68	69	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		C047426	39786
venlafaxine hydrochloride	venlafaxine	68	70	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		C047426	39786
venlafaxine hydrochloride	venlafaxine	68	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		C047426	39786
venlafaxine hydrochloride	venlafaxine	17	17	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  		C047426	39786
venlafaxine hydrochloride	venlafaxine	17	16	false	none	Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  		C047426	39786
venlafaxine hydrochloride	venlafaxine	17	19	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		C047426	39786
venlafaxine hydrochloride	venlafaxine	17	18	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		C047426	39786
venlafaxine hydrochloride	venlafaxine	67	68	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  		C047426	39786
venlafaxine hydrochloride	venlafaxine	67	69	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		C047426	39786
venlafaxine hydrochloride	venlafaxine	67	67	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		C047426	39786
venlafaxine hydrochloride	venlafaxine	59	59	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		C047426	39786
venlafaxine hydrochloride	venlafaxine	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		C047426	39786
venlafaxine hydrochloride	venlafaxine	59	57	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		C047426	39786
venlafaxine hydrochloride	venlafaxine	59	60	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		C047426	39786
venlafaxine hydrochloride	venlafaxine	42	42	false	none	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		C047426	39786
venlafaxine hydrochloride	venlafaxine	42	43	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		C047426	39786
venlafaxine hydrochloride	venlafaxine	42	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		C047426	39786
venlafaxine hydrochloride	venlafaxine	42	41	false	none	Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		C047426	39786
venlafaxine hydrochloride	venlafaxine	42	44	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		C047426	39786
venlafaxine hydrochloride	venlafaxine	58	59	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		C047426	39786
venlafaxine hydrochloride	venlafaxine	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		C047426	39786
venlafaxine hydrochloride	venlafaxine	58	57	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		C047426	39786
venlafaxine hydrochloride	venlafaxine	58	56	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		C047426	39786
venlafaxine hydrochloride	venlafaxine	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		C047426	39786
venlafaxine hydrochloride	venlafaxine	62	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		C047426	39786
venlafaxine hydrochloride	venlafaxine	62	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		C047426	39786
venlafaxine hydrochloride	venlafaxine	60	59	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		C047426	39786
venlafaxine hydrochloride	venlafaxine	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		C047426	39786
venlafaxine hydrochloride	venlafaxine	60	62	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		C047426	39786
venlafaxine hydrochloride	venlafaxine	60	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		C047426	39786
venlafaxine hydrochloride	tryptophan	59	60	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	tryptophan	59	60	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	tryptophan	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	tryptophan	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	tryptophan	62	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	tryptophan	62	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	tryptophan	60	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	tryptophan	60	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	Metoprolol	42	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		39786	6918	C047426	D008790
venlafaxine hydrochloride	Metoprolol	42	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		39786	6918	C047426	D008790
venlafaxine hydrochloride	9-hydroxyrisperidone	42	43	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		39786	none	C047426	none
venlafaxine hydrochloride	9-hydroxyrisperidone	42	43	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		39786	none	C047426	none
venlafaxine hydrochloride	9-hydroxyrisperidone	42	44	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	none	C047426	none
venlafaxine hydrochloride	9-hydroxyrisperidone	42	44	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	none	C047426	none
venlafaxine hydrochloride	clozapine	68	69	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		39786	none	C047426	none
venlafaxine hydrochloride	clozapine	68	69	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		39786	none	C047426	none
venlafaxine hydrochloride	clozapine	67	69	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		39786	none	C047426	none
venlafaxine hydrochloride	clozapine	67	69	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		39786	none	C047426	none
venlafaxine hydrochloride	metoprolol	42	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		39786	6918	C047426	D008790
venlafaxine hydrochloride	metoprolol	42	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		39786	6918	C047426	D008790
venlafaxine hydrochloride	p450	17	18	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		39786	none	C047426	none
venlafaxine hydrochloride	p450	17	18	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		39786	none	C047426	none
venlafaxine hydrochloride	triptan	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	triptan	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	triptan	59	61	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		39786	none	C047426	none
venlafaxine hydrochloride	triptan	59	61	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		39786	none	C047426	none
venlafaxine hydrochloride	triptan	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	triptan	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	triptan	62	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	triptan	62	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	triptan	62	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	triptan	62	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	triptan	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	triptan	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	triptan	60	62	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	triptan	60	62	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	C047426	none
venlafaxine hydrochloride	triptan	60	61	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		39786	none	C047426	none
venlafaxine hydrochloride	triptan	60	61	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		39786	none	C047426	none
aspirin	serotonin	65	64	false	none	Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  		none	none	none	none
aspirin	serotonin	65	63	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  		none	none	none	none
aspirin	serotonin	63	64	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  		none	none	none	none
aspirin	serotonin	63	63	false	none	7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
aspirin	serotonin	63	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
aspirin	venlafaxine	65	67	false	none	These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	39786
aspirin	venlafaxine	65	67	false	none	These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.  Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin.  Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  		none	39786	none	39786
aspirin	venlafaxine	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	39786	none	39786
aspirin	venlafaxine	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	39786	none	39786
aspirin	triptan	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
aspirin	triptan	63	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
risperidone	terfenadine	44	46	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	none	none	none
risperidone	venlafaxine	43	42	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	39786	none	39786
risperidone	venlafaxine	43	42	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	39786	none	39786
risperidone	venlafaxine	43	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	39786	none	39786
risperidone	venlafaxine	43	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	39786	none	39786
risperidone	venlafaxine	43	41	true	positive	Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	39786	none	39786
risperidone	venlafaxine	43	41	true	positive	Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	39786	none	39786
risperidone	venlafaxine	43	44	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	39786
risperidone	venlafaxine	43	44	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	39786
risperidone	venlafaxine	43	45	true	negative	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  		none	39786	none	39786
risperidone	venlafaxine	43	45	true	negative	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  		none	39786	none	39786
risperidone	venlafaxine	44	42	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	39786
risperidone	venlafaxine	44	42	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	39786
risperidone	venlafaxine	44	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	39786
risperidone	venlafaxine	44	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	39786
risperidone	venlafaxine	44	46	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	39786	none	39786
risperidone	venlafaxine	44	46	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	39786	none	39786
risperidone	venlafaxine	44	44	false	none	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	39786
risperidone	venlafaxine	44	44	false	none	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	39786	none	39786
risperidone	venlafaxine	44	45	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  		none	39786	none	39786
risperidone	venlafaxine	44	45	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  		none	39786	none	39786
risperidone	9-hydroxyrisperidone	43	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		none	none	none	none
risperidone	9-hydroxyrisperidone	43	44	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	none	none	none
risperidone	9-hydroxyrisperidone	44	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	none	none	none
risperidone	9-hydroxyrisperidone	44	44	false	none	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		none	none	none	none
fluoxetine	desipramine	30	32	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		4493	3247	D005473	3247
fluoxetine	desipramine	30	32	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		4493	3247	D005473	3247
fluoxetine	venlafaxine	30	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		4493	39786	D005473	39786
fluoxetine	venlafaxine	30	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		4493	39786	D005473	39786
fluoxetine	venlafaxine	30	28	false	none	Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		4493	39786	D005473	39786
fluoxetine	venlafaxine	30	28	false	none	Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		4493	39786	D005473	39786
fluoxetine	venlafaxine	30	31	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		4493	39786	D005473	39786
fluoxetine	venlafaxine	30	31	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		4493	39786	D005473	39786
fluoxetine	venlafaxine	30	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		4493	39786	D005473	39786
fluoxetine	venlafaxine	30	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		4493	39786	D005473	39786
fluoxetine	venlafaxine	30	32	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		4493	39786	D005473	39786
fluoxetine	venlafaxine	30	32	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		4493	39786	D005473	39786
fluoxetine	dextromethorphan	30	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		4493	0	D005473	D003915
fluoxetine	dextromethorphan	30	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		4493	0	D005473	D003915
fluoxetine	p450	30	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		4493	none	D005473	none
fluoxetine	p450	30	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		4493	none	D005473	none
terfenadine	indinavir	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	none	none	none
terfenadine	indinavir	46	47	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		none	none	none	none
terfenadine	venlafaxine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	39786	none	39786
terfenadine	venlafaxine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	39786	none	39786
terfenadine	venlafaxine	46	47	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		none	39786	none	39786
terfenadine	venlafaxine	46	47	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		none	39786	none	39786
terfenadine	venlafaxine	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	39786	none	39786
terfenadine	venlafaxine	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	39786	none	39786
terfenadine	venlafaxine	46	45	true	negative	CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	39786	none	39786
terfenadine	venlafaxine	46	45	true	negative	CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	39786	none	39786
terfenadine	venlafaxine	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
terfenadine	venlafaxine	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
terfenadine	9-hydroxyrisperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		none	none	none	none
tolbutamide	venlafaxine	53	51	false	none	This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  		none	39786	none	39786
tolbutamide	venlafaxine	53	51	false	none	This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.  CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  		none	39786	none	39786
tolbutamide	venlafaxine	53	54	false	none	In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		none	39786	none	39786
tolbutamide	venlafaxine	53	54	false	none	In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  		none	39786	none	39786
tolbutamide	venlafaxine	53	53	false	none	In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  		none	39786	none	39786
tolbutamide	venlafaxine	53	53	false	none	In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  		none	39786	none	39786
tolbutamide	venlafaxine	53	52	false	none	CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  		none	39786	none	39786
tolbutamide	venlafaxine	53	52	false	none	CYP2C9     Venlafaxine did not inhibit CYP2C9 in vitro.  In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.  		none	39786	none	39786
serotonin	linezolid	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	none	none	none
serotonin	tramadol	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	none	none	none
serotonin	venlafaxine	64	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  		none	39786	none	39786
serotonin	venlafaxine	64	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  		none	39786	none	39786
serotonin	venlafaxine	58	59	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
serotonin	venlafaxine	58	59	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
serotonin	venlafaxine	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
serotonin	venlafaxine	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
serotonin	venlafaxine	58	57	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
serotonin	venlafaxine	58	57	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
serotonin	venlafaxine	58	56	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
serotonin	venlafaxine	58	56	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
serotonin	venlafaxine	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
serotonin	venlafaxine	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
serotonin	venlafaxine	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	39786	none	39786
serotonin	venlafaxine	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	39786	none	39786
serotonin	venlafaxine	61	59	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	39786	none	39786
serotonin	venlafaxine	61	59	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	39786	none	39786
serotonin	venlafaxine	61	62	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
serotonin	venlafaxine	61	62	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
serotonin	venlafaxine	61	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	39786	none	39786
serotonin	venlafaxine	61	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	39786	none	39786
serotonin	tryptophan	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	none	none	none
serotonin	tryptophan	61	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	none	none	none
serotonin	triptan	64	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.  		none	none	none	none
serotonin	triptan	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	none	none	none
serotonin	triptan	63	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
serotonin	triptan	63	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)    Serotonin release by platelets plays an important role in hemostasis.  		none	none	none	none
serotonin	triptan	61	62	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	none	none	none
serotonin	triptan	61	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	none	none	none
desmethyldiazepam	venlafaxine	10	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3155	39786	D003708	39786
desmethyldiazepam	venlafaxine	10	9	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3155	39786	D003708	39786
desmethyldiazepam	venlafaxine	10	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3155	39786	D003708	39786
desmethyldiazepam	venlafaxine	10	10	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  		3155	39786	D003708	39786
desmethyldiazepam	venlafaxine	10	11	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3155	39786	D003708	39786
desmethyldiazepam	venlafaxine	10	11	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3155	39786	D003708	39786
desmethyldiazepam	venlafaxine	10	12	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		3155	39786	D003708	39786
desmethyldiazepam	venlafaxine	10	12	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		3155	39786	D003708	39786
desmethyldiazepam	Haloperidol	10	11	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3155	5093	D003708	D006220
desmethyldiazepam	Haloperidol	10	11	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		3155	5093	D003708	D006220
desmethyldiazepam	Haloperidol	10	12	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		3155	5093	D003708	D006220
desmethyldiazepam	Haloperidol	10	12	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		3155	5093	D003708	D006220
desipramine	venlafaxine	35	34	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  		3247	39786	3247	39786
desipramine	venlafaxine	35	34	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  		3247	39786	3247	39786
desipramine	venlafaxine	35	33	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  		3247	39786	3247	39786
desipramine	venlafaxine	35	33	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  		3247	39786	3247	39786
desipramine	venlafaxine	35	36	true	negative	The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		3247	39786	3247	39786
desipramine	venlafaxine	35	36	true	negative	The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		3247	39786	3247	39786
desipramine	venlafaxine	35	37	true	negative	The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		3247	39786	3247	39786
desipramine	venlafaxine	35	37	true	negative	The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		3247	39786	3247	39786
desipramine	venlafaxine	32	31	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		3247	39786	3247	39786
desipramine	venlafaxine	32	31	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		3247	39786	3247	39786
desipramine	venlafaxine	32	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		3247	39786	3247	39786
desipramine	venlafaxine	32	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		3247	39786	3247	39786
desipramine	venlafaxine	32	34	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		3247	39786	3247	39786
desipramine	venlafaxine	32	34	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		3247	39786	3247	39786
desipramine	venlafaxine	32	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		3247	39786	3247	39786
desipramine	venlafaxine	32	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		3247	39786	3247	39786
desipramine	venlafaxine	32	33	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		3247	39786	3247	39786
desipramine	venlafaxine	32	33	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		3247	39786	3247	39786
desipramine	venlafaxine	33	31	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		3247	39786	3247	39786
desipramine	venlafaxine	33	31	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		3247	39786	3247	39786
desipramine	venlafaxine	33	34	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		3247	39786	3247	39786
desipramine	venlafaxine	33	34	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  		3247	39786	3247	39786
desipramine	venlafaxine	33	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		3247	39786	3247	39786
desipramine	venlafaxine	33	32	false	none	However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		3247	39786	3247	39786
desipramine	venlafaxine	33	33	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		3247	39786	3247	39786
desipramine	venlafaxine	33	33	false	none	The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).  		3247	39786	3247	39786
desipramine	Metoprolol	35	36	true	negative	The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		3247	6918	3247	D008790
desipramine	Metoprolol	35	36	true	negative	The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		3247	6918	3247	D008790
desipramine	Metoprolol	35	37	true	negative	The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		3247	6918	3247	D008790
desipramine	Metoprolol	35	37	true	negative	The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		3247	6918	3247	D008790
desipramine	dextromethorphan	32	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		3247	0	3247	D003915
desipramine	dextromethorphan	32	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		3247	0	3247	D003915
desipramine	metoprolol	35	36	true	negative	The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		3247	6918	3247	D008790
desipramine	metoprolol	35	36	true	negative	The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		3247	6918	3247	D008790
desipramine	metoprolol	35	37	true	negative	The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		3247	6918	3247	D008790
desipramine	metoprolol	35	37	true	negative	The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		3247	6918	3247	D008790
linezolid	tramadol	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	none	none	none
linezolid	venlafaxine	58	59	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
linezolid	venlafaxine	58	59	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
linezolid	venlafaxine	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
linezolid	venlafaxine	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
linezolid	venlafaxine	58	57	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
linezolid	venlafaxine	58	57	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
linezolid	venlafaxine	58	56	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
linezolid	venlafaxine	58	56	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
linezolid	venlafaxine	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
linezolid	venlafaxine	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
linezolid	tryptophan	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	none	none	none
linezolid	triptan	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	none	none	none
tramadol	venlafaxine	58	59	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
tramadol	venlafaxine	58	59	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	39786	none	39786
tramadol	venlafaxine	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
tramadol	venlafaxine	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
tramadol	venlafaxine	58	57	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
tramadol	venlafaxine	58	57	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
tramadol	venlafaxine	58	56	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
tramadol	venlafaxine	58	56	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	39786	none	39786
tramadol	venlafaxine	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
tramadol	venlafaxine	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	39786	none	39786
tramadol	tryptophan	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	none	none	none
tramadol	triptan	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		none	none	none	none
ethanol	venlafaxine	1	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  		448	39786	D000431	39786
ethanol	venlafaxine	1	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  		448	39786	D000431	39786
ethanol	venlafaxine	1	2	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  		448	39786	D000431	39786
ethanol	venlafaxine	1	2	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  		448	39786	D000431	39786
ethanol	venlafaxine	1	3	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		448	39786	D000431	39786
ethanol	venlafaxine	1	3	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		448	39786	D000431	39786
ethanol	venlafaxine	2	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  		448	39786	D000431	39786
ethanol	venlafaxine	2	1	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  		448	39786	D000431	39786
ethanol	venlafaxine	2	2	false	none	Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  		448	39786	D000431	39786
ethanol	venlafaxine	2	2	false	none	Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  		448	39786	D000431	39786
ethanol	venlafaxine	2	3	false	none	Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		448	39786	D000431	39786
ethanol	venlafaxine	2	3	false	none	Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		448	39786	D000431	39786
ethanol	venlafaxine	2	4	false	none	Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  		448	39786	D000431	39786
ethanol	venlafaxine	2	4	false	none	Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  		448	39786	D000431	39786
ethanol	Cimetidine	1	3	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		448	2541	D000431	2541
ethanol	Cimetidine	1	3	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		448	2541	D000431	2541
ethanol	Cimetidine	2	3	false	none	Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		448	2541	D000431	2541
ethanol	Cimetidine	2	3	false	none	Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		448	2541	D000431	2541
indinavir	venlafaxine	48	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
indinavir	venlafaxine	48	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
indinavir	venlafaxine	48	47	true	negative	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
indinavir	venlafaxine	48	47	true	negative	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
indinavir	venlafaxine	48	50	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of this finding is unknown.  CYP1A2    Venlafaxine did not inhibit CYP1A2 in vitro.  		none	39786	none	39786
indinavir	venlafaxine	48	50	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of this finding is unknown.  CYP1A2    Venlafaxine did not inhibit CYP1A2 in vitro.  		none	39786	none	39786
indinavir	venlafaxine	48	48	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
indinavir	venlafaxine	48	48	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
indinavir	venlafaxine	47	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		none	39786	none	39786
indinavir	venlafaxine	47	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		none	39786	none	39786
indinavir	venlafaxine	47	47	false	none	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		none	39786	none	39786
indinavir	venlafaxine	47	47	false	none	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		none	39786	none	39786
indinavir	venlafaxine	47	45	true	negative	CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		none	39786	none	39786
indinavir	venlafaxine	47	45	true	negative	CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  		none	39786	none	39786
indinavir	venlafaxine	47	48	true	negative	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
indinavir	venlafaxine	47	48	true	negative	Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.  		none	39786	none	39786
venlafaxine	tryptophan	59	60	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	39786	none
venlafaxine	tryptophan	59	60	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	39786	none
venlafaxine	tryptophan	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	39786	none
venlafaxine	tryptophan	58	60	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	39786	none
venlafaxine	tryptophan	62	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
venlafaxine	tryptophan	62	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
venlafaxine	tryptophan	60	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	39786	none
venlafaxine	tryptophan	60	60	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	39786	none
venlafaxine	Metoprolol	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		39786	6918	39786	D008790
venlafaxine	Metoprolol	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		39786	6918	39786	D008790
venlafaxine	Metoprolol	38	38	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
venlafaxine	Metoprolol	38	38	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
venlafaxine	Metoprolol	38	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
venlafaxine	Metoprolol	38	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
venlafaxine	Metoprolol	38	37	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
venlafaxine	Metoprolol	38	37	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
venlafaxine	Metoprolol	38	40	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  The clinical relevance of this finding for hypertensive patients is unknown.  Caution should be exercised with co-administration of venlafaxine and metoprolol.  		39786	6918	39786	D008790
venlafaxine	Metoprolol	38	40	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  The clinical relevance of this finding for hypertensive patients is unknown.  Caution should be exercised with co-administration of venlafaxine and metoprolol.  		39786	6918	39786	D008790
venlafaxine	Metoprolol	36	38	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
venlafaxine	Metoprolol	36	38	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
venlafaxine	Metoprolol	36	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		39786	6918	39786	D008790
venlafaxine	Metoprolol	36	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		39786	6918	39786	D008790
venlafaxine	Metoprolol	36	37	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		39786	6918	39786	D008790
venlafaxine	Metoprolol	36	37	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		39786	6918	39786	D008790
venlafaxine	Metoprolol	37	38	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
venlafaxine	Metoprolol	37	38	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
venlafaxine	Metoprolol	37	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		39786	6918	39786	D008790
venlafaxine	Metoprolol	37	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		39786	6918	39786	D008790
venlafaxine	Metoprolol	37	37	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		39786	6918	39786	D008790
venlafaxine	Metoprolol	37	37	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		39786	6918	39786	D008790
venlafaxine	Metoprolol	42	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		39786	6918	39786	D008790
venlafaxine	Metoprolol	42	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		39786	6918	39786	D008790
venlafaxine	Metoprolol	40	38	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  The clinical relevance of this finding for hypertensive patients is unknown.  Caution should be exercised with co-administration of venlafaxine and metoprolol.  		39786	6918	39786	D008790
venlafaxine	Metoprolol	40	38	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  The clinical relevance of this finding for hypertensive patients is unknown.  Caution should be exercised with co-administration of venlafaxine and metoprolol.  		39786	6918	39786	D008790
venlafaxine	Metoprolol	40	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  		39786	6918	39786	D008790
venlafaxine	Metoprolol	40	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  		39786	6918	39786	D008790
venlafaxine	Metoprolol	41	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  		39786	6918	39786	D008790
venlafaxine	Metoprolol	41	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  		39786	6918	39786	D008790
venlafaxine	Haloperidol	9	11	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		39786	5093	39786	D006220
venlafaxine	Haloperidol	9	11	false	none	7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		39786	5093	39786	D006220
venlafaxine	Haloperidol	10	11	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		39786	5093	39786	D006220
venlafaxine	Haloperidol	10	11	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		39786	5093	39786	D006220
venlafaxine	Haloperidol	10	12	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		39786	5093	39786	D006220
venlafaxine	Haloperidol	10	12	false	none	Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.  7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		39786	5093	39786	D006220
venlafaxine	Haloperidol	11	11	true	positive	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		39786	5093	39786	D006220
venlafaxine	Haloperidol	11	11	true	positive	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  		39786	5093	39786	D006220
venlafaxine	Haloperidol	11	12	false	none	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		39786	5093	39786	D006220
venlafaxine	Haloperidol	11	12	false	none	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		39786	5093	39786	D006220
venlafaxine	Haloperidol	12	11	false	none	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		39786	5093	39786	D006220
venlafaxine	Haloperidol	12	11	false	none	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.  In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		39786	5093	39786	D006220
venlafaxine	Haloperidol	12	12	false	none	In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		39786	5093	39786	D006220
venlafaxine	Haloperidol	12	12	false	none	In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  		39786	5093	39786	D006220
venlafaxine	Haloperidol	14	12	true	negative	In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  The mechanism explaining this finding is unknown.  7.5 Lithium    The steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects.  		39786	5093	39786	D006220
venlafaxine	Haloperidol	14	12	true	negative	In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.  The mechanism explaining this finding is unknown.  7.5 Lithium    The steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects.  		39786	5093	39786	D006220
venlafaxine	9-hydroxyrisperidone	42	43	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		39786	none	39786	none
venlafaxine	9-hydroxyrisperidone	42	43	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		39786	none	39786	none
venlafaxine	9-hydroxyrisperidone	42	44	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	none	39786	none
venlafaxine	9-hydroxyrisperidone	42	44	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	none	39786	none
venlafaxine	9-hydroxyrisperidone	43	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		39786	none	39786	none
venlafaxine	9-hydroxyrisperidone	43	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		39786	none	39786	none
venlafaxine	9-hydroxyrisperidone	43	44	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	none	39786	none
venlafaxine	9-hydroxyrisperidone	43	44	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	none	39786	none
venlafaxine	9-hydroxyrisperidone	41	43	true	positive	Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		39786	none	39786	none
venlafaxine	9-hydroxyrisperidone	41	43	true	positive	Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  		39786	none	39786	none
venlafaxine	9-hydroxyrisperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		39786	none	39786	none
venlafaxine	9-hydroxyrisperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  		39786	none	39786	none
venlafaxine	9-hydroxyrisperidone	44	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	none	39786	none
venlafaxine	9-hydroxyrisperidone	44	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	none	39786	none
venlafaxine	9-hydroxyrisperidone	44	44	false	none	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	none	39786	none
venlafaxine	9-hydroxyrisperidone	44	44	false	none	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  		39786	none	39786	none
venlafaxine	9-hydroxyrisperidone	45	43	true	negative	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  		39786	none	39786	none
venlafaxine	9-hydroxyrisperidone	45	43	true	negative	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.  However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  		39786	none	39786	none
venlafaxine	9-hydroxyrisperidone	45	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  		39786	none	39786	none
venlafaxine	9-hydroxyrisperidone	45	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  		39786	none	39786	none
venlafaxine	dextromethorphan	29	30	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		39786	0	39786	D003915
venlafaxine	dextromethorphan	29	30	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		39786	0	39786	D003915
venlafaxine	dextromethorphan	28	30	false	none	Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		39786	0	39786	D003915
venlafaxine	dextromethorphan	28	30	false	none	Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		39786	0	39786	D003915
venlafaxine	dextromethorphan	31	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		39786	0	39786	D003915
venlafaxine	dextromethorphan	31	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		39786	0	39786	D003915
venlafaxine	dextromethorphan	30	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		39786	0	39786	D003915
venlafaxine	dextromethorphan	30	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		39786	0	39786	D003915
venlafaxine	dextromethorphan	32	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		39786	0	39786	D003915
venlafaxine	dextromethorphan	32	30	false	none	These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  		39786	0	39786	D003915
venlafaxine	clozapine	68	69	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		39786	none	39786	none
venlafaxine	clozapine	68	69	false	none	[See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		39786	none	39786	none
venlafaxine	clozapine	69	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		39786	none	39786	none
venlafaxine	clozapine	69	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		39786	none	39786	none
venlafaxine	clozapine	70	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		39786	none	39786	none
venlafaxine	clozapine	70	69	false	none	7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.  		39786	none	39786	none
venlafaxine	clozapine	67	69	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		39786	none	39786	none
venlafaxine	clozapine	67	69	false	none	Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued.  [See Warnings and Precautions (5.14)]    7.12 Electroconvulsive Therapy    There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment.  7.13 Postmarketing Spontaneous Drug Interaction Reports    There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.  		39786	none	39786	none
venlafaxine	Cimetidine	1	3	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		39786	2541	39786	2541
venlafaxine	Cimetidine	1	3	false	none	7 DRUG INTERACTIONS    7.1 Alcohol    A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.  Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		39786	2541	39786	2541
venlafaxine	Cimetidine	2	3	false	none	Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		39786	2541	39786	2541
venlafaxine	Cimetidine	2	3	false	none	Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.  7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		39786	2541	39786	2541
venlafaxine	Cimetidine	3	3	true	positive	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		39786	2541	39786	2541
venlafaxine	Cimetidine	3	3	true	positive	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  		39786	2541	39786	2541
venlafaxine	Cimetidine	3	5	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		39786	2541	39786	2541
venlafaxine	Cimetidine	3	5	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		39786	2541	39786	2541
venlafaxine	Cimetidine	4	3	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  		39786	2541	39786	2541
venlafaxine	Cimetidine	4	3	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  		39786	2541	39786	2541
venlafaxine	Cimetidine	4	5	false	none	The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		39786	2541	39786	2541
venlafaxine	Cimetidine	4	5	false	none	The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		39786	2541	39786	2541
venlafaxine	Cimetidine	5	3	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		39786	2541	39786	2541
venlafaxine	Cimetidine	5	3	false	none	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.  The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.  However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		39786	2541	39786	2541
venlafaxine	Cimetidine	5	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		39786	2541	39786	2541
venlafaxine	Cimetidine	5	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  		39786	2541	39786	2541
venlafaxine	Cimetidine	5	7	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		39786	2541	39786	2541
venlafaxine	Cimetidine	5	7	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		39786	2541	39786	2541
venlafaxine	Cimetidine	6	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		39786	2541	39786	2541
venlafaxine	Cimetidine	6	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  		39786	2541	39786	2541
venlafaxine	Cimetidine	6	7	false	none	The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		39786	2541	39786	2541
venlafaxine	Cimetidine	6	7	false	none	The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		39786	2541	39786	2541
venlafaxine	Cimetidine	7	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		39786	2541	39786	2541
venlafaxine	Cimetidine	7	5	false	none	However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.  The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.  However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		39786	2541	39786	2541
venlafaxine	Cimetidine	7	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		39786	2541	39786	2541
venlafaxine	Cimetidine	7	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  		39786	2541	39786	2541
venlafaxine	Cimetidine	9	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		39786	2541	39786	2541
venlafaxine	Cimetidine	9	7	false	none	However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced.  Therefore, caution is advised with such patients.  7.3 Diazepam    Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.  		39786	2541	39786	2541
venlafaxine	metoprolol	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		39786	6918	39786	D008790
venlafaxine	metoprolol	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		39786	6918	39786	D008790
venlafaxine	metoprolol	38	38	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
venlafaxine	metoprolol	38	38	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
venlafaxine	metoprolol	38	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
venlafaxine	metoprolol	38	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
venlafaxine	metoprolol	38	37	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
venlafaxine	metoprolol	38	37	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
venlafaxine	metoprolol	38	40	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  The clinical relevance of this finding for hypertensive patients is unknown.  Caution should be exercised with co-administration of venlafaxine and metoprolol.  		39786	6918	39786	D008790
venlafaxine	metoprolol	38	40	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  The clinical relevance of this finding for hypertensive patients is unknown.  Caution should be exercised with co-administration of venlafaxine and metoprolol.  		39786	6918	39786	D008790
venlafaxine	metoprolol	36	38	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
venlafaxine	metoprolol	36	38	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
venlafaxine	metoprolol	36	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		39786	6918	39786	D008790
venlafaxine	metoprolol	36	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		39786	6918	39786	D008790
venlafaxine	metoprolol	36	37	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		39786	6918	39786	D008790
venlafaxine	metoprolol	36	37	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		39786	6918	39786	D008790
venlafaxine	metoprolol	37	38	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
venlafaxine	metoprolol	37	38	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		39786	6918	39786	D008790
venlafaxine	metoprolol	37	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		39786	6918	39786	D008790
venlafaxine	metoprolol	37	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		39786	6918	39786	D008790
venlafaxine	metoprolol	37	37	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		39786	6918	39786	D008790
venlafaxine	metoprolol	37	37	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		39786	6918	39786	D008790
venlafaxine	metoprolol	42	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		39786	6918	39786	D008790
venlafaxine	metoprolol	42	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  		39786	6918	39786	D008790
venlafaxine	metoprolol	40	38	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  The clinical relevance of this finding for hypertensive patients is unknown.  Caution should be exercised with co-administration of venlafaxine and metoprolol.  		39786	6918	39786	D008790
venlafaxine	metoprolol	40	38	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  The clinical relevance of this finding for hypertensive patients is unknown.  Caution should be exercised with co-administration of venlafaxine and metoprolol.  		39786	6918	39786	D008790
venlafaxine	metoprolol	40	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  		39786	6918	39786	D008790
venlafaxine	metoprolol	40	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  		39786	6918	39786	D008790
venlafaxine	metoprolol	41	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  		39786	6918	39786	D008790
venlafaxine	metoprolol	41	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  		39786	6918	39786	D008790
venlafaxine	p450	17	18	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		39786	none	39786	none
venlafaxine	p450	17	18	false	none	7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		39786	none	39786	none
venlafaxine	p450	16	18	false	none	Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		39786	none	39786	none
venlafaxine	p450	16	18	false	none	Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).  7.6 Drugs Highly Bound to Plasma Proteins    Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.  7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		39786	none	39786	none
venlafaxine	p450	19	18	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		39786	none	39786	none
venlafaxine	p450	19	18	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite.  		39786	none	39786	none
venlafaxine	p450	18	18	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		39786	none	39786	none
venlafaxine	p450	18	18	false	none	7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes    CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.  		39786	none	39786	none
venlafaxine	p450	27	29	false	none	Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  		39786	none	39786	none
venlafaxine	p450	27	29	false	none	Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV.  Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  		39786	none	39786	none
venlafaxine	p450	29	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  		39786	none	39786	none
venlafaxine	p450	29	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  		39786	none	39786	none
venlafaxine	p450	28	29	false	none	Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  		39786	none	39786	none
venlafaxine	p450	28	29	false	none	Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.  7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  		39786	none	39786	none
venlafaxine	p450	31	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		39786	none	39786	none
venlafaxine	p450	31	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  		39786	none	39786	none
venlafaxine	p450	30	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		39786	none	39786	none
venlafaxine	p450	30	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		39786	none	39786	none
venlafaxine	triptan	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
venlafaxine	triptan	59	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
venlafaxine	triptan	59	61	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		39786	none	39786	none
venlafaxine	triptan	59	61	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		39786	none	39786	none
venlafaxine	triptan	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
venlafaxine	triptan	58	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
venlafaxine	triptan	57	58	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
venlafaxine	triptan	57	58	false	none	Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
venlafaxine	triptan	56	58	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
venlafaxine	triptan	56	58	false	none	7.10 Other CNS-Active Drugs    The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).  Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required.  Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  		39786	none	39786	none
venlafaxine	triptan	62	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
venlafaxine	triptan	62	62	false	none	If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
venlafaxine	triptan	62	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
venlafaxine	triptan	62	61	false	none	Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
venlafaxine	triptan	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	39786	none
venlafaxine	triptan	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		39786	none	39786	none
venlafaxine	triptan	60	62	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
venlafaxine	triptan	60	62	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		39786	none	39786	none
venlafaxine	triptan	60	61	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		39786	none	39786	none
venlafaxine	triptan	60	61	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		39786	none	39786	none
tryptophan	triptan	60	58	false	none	Serotonergic Drugs    Based on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)].  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  		none	none	none	none
tryptophan	triptan	60	62	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)].  		none	none	none	none
tryptophan	triptan	60	61	false	none	The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)].  Triptans    There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	none	none	none
Metoprolol	metoprolol	38	38	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		D008790	D008790
Metoprolol	metoprolol	38	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		D008790	D008790
Metoprolol	metoprolol	38	37	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		D008790	D008790
Metoprolol	metoprolol	38	40	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  The clinical relevance of this finding for hypertensive patients is unknown.  Caution should be exercised with co-administration of venlafaxine and metoprolol.  		D008790	D008790
Metoprolol	metoprolol	36	38	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		D008790	D008790
Metoprolol	metoprolol	36	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  		D008790	D008790
Metoprolol	metoprolol	36	37	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		D008790	D008790
Metoprolol	metoprolol	37	38	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  		D008790	D008790
Metoprolol	metoprolol	37	36	true	negative	Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		D008790	D008790
Metoprolol	metoprolol	37	37	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  		D008790	D008790
Metoprolol	metoprolol	40	38	false	none	Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.  The clinical relevance of this finding for hypertensive patients is unknown.  Caution should be exercised with co-administration of venlafaxine and metoprolol.  		D008790	D008790
Metoprolol	metoprolol	40	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  		D008790	D008790
dextromethorphan	p450	30	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		0	none	D003915	none
dextromethorphan	p450	30	29	false	none	7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes    CYP2D6    In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.  These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.  		0	none	D003915	none
